deep vein thrombosis'

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the informa needed to use LOPINAVIR AND RITONAVIR TABLETS safely and effectively. See full prescribing information for LOPINAVIR AND RITONAVIR TABLETS. LOPINAVIR AND RITONAVIR tablets, for oral use

Initial U.S. Approval: 2000 ----RECENT MAJOR CHANGES-12/2019 Contraindications (4) The following have been observed in patients receiving ----INDICATIONS AND USAGE-------DOSAGE AND ADMINISTRATION---

Lopinavir and ritonavir is an HIV-1 protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (14 days and older). (1) Tablets: May be taken with or without food, swallowed whole and not chewed, broken, or crushed. (2.1) Oral solution: must be taken with food. (2.1)

Adults (2.3): Total recommended daily dosage is 800/200 mg given once or twice daily. Lopinavir and ritonavir can be given as once daily or twice daily regimen. See Full Prescribing Information

Pancreatitis: Fatalities have occurred; suspend therapy as clinically appropriate. (5.3) Hepatotoxicity: Fatalities have occurred. Monitor liver function before and during therapy, especially in patients for details. with underlying hepatic disease, including hepatitis B Lopinavir and ritonavir once daily dosing regimen is not and hepatitis C, or marked transaminase elevations. ommended in:
Adult patients with three or more of the following (5.4, 8.6)QT interval prolongation and isolated cases of torsade de pointes have been reported although causality could not be established. Avoid use in patients with congenital lopinavir resistance-associated substitutions

L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. (12.4) long QT syndrome those with hypokalemia and with In combination with carbamazepine, phenobarbital, er drugs that prolong the QT interval. (5.1, 5.5, 12.3) or phenytoin. (7.3)
In combination with efavirenz, nevirapine, or PR interval prolongation may occur in some patients. Cases of second and third degree heart block have been reported. Use with caution in patients with prenelfinavir. (12.3) • In pregnant women. (2.5, 8.1, 12.3) existing conduction system disease, ischemic heart disease, cardiomyopathy, underlying structural heart disease or when administering with other drugs that may prolong the PR interval. (5.1, 5.6, 12.3) Pediatric Patients (14 days and older) (2.4): Lopinavir and ritonavir once daily dosing regimen is not recommended in pediatric patients.

Twice daily dose is based on body weight or body Patients may develop new onset or exacerbations

of diabetes mellitus, hyperglycemia (5.7), immune reconstitution syndrome (5.8), redistribution/ surface area. Concomitant Therapy in Adults and Pediatric Patients: accumulation of body fat. (5.10) Dose adjustments of lopinavir and ritonavir may be needed when co-administering with efavirenz, Total cholesterol and triglycerides elevations. Monitor prior to therapy and periodically thereafter. (5.9) nevirapine, or nelfinavir. (2.3, 2.4, 7.3) Hemophilia: Spontaneous bleeding may occur, and additional factor VIII may be required. (5.11) Lopinavir and ritonavir oral solution should not be administered to neonates before a postmenstrual age --ADVERSE REACTIONS--(first day of the mother's last menstrual period to birth plu the time elapsed after birth) of 42 weeks and a postnatal

Commonly reported adverse reactions to lopinavir and ritonavir included diarrhea, nausea, vomiting, hypertriglyceridemia and hypercholesterolemia. (6.1) Pregnancy (2.5):

• 400/100 mg twice daily in pregnant patients with To report SUSPECTED ADVERSE REACTIONS, contact no documented lopinavir-associated resistance Laurus Generics Inc. at 1-833-3-LAURUS (1-833-352-8787) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch There are insufficient data to recommend a lopinavir ----DRUG INTERACTIONS--and ritonavir dose for pregnant patients with any documented lopinavir and ritonavir-associated resistance substitutions. Co-administration of lopinavir and ritonavir can alter the plasma concentrations of other drugs and other drugs may No dose adjustment of lopinavir and ritonavir is required

Co-administration with drugs highly dependent on

CYP3A for clearance and for which elevated plasma

Co-administration with potent CYP3A inducers where

significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic

response and possible resistance and cross resistance. (4)

The concomitant use of lopinavir and ritonavir and

certain other drugs may result in known or potentially significant drug interactions. Consult the full prescribing

information prior to and during treatment for potential

drug interactions. (5.1, 7.3)

Toxicity in preterm neonates: Lopinavir and ritonavir

oral solution should not be used in preterm neonates in the immediate postnatal period because of possible toxicities. A safe and effective dose of lopinavir and

ritonavir oral solution in this patient population has not

n established. (2.4, 5.2)

-----WARNINGS AND PRECAUTIONS---

events. (4)

levels may result in serious and/or life- threatening

alter the plasma concentrations of lopinavir. The potential for drug-drug interactions must be considered prior to and during therapy. (4, 5.1, 7, 12.3) ----USE IN SPECIFIC POPULATIONS--Lactation: Breastfeeding not recommended. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Revised: 05/2023

FULL PRESCRIBING INFORMATION: CONTENTS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION

its ingredients, including ritonavir. (4)

substitutions

2.1 General Administration Recommendations

for patients during the postpartum period

Tablets: 100 mg lopinavir and 25 mg ritonavir (3)

----DOSAGE FORMS AND STRENGTHS ----

Tablets: 200 mg lopinavir and 50 mg ritonavir (3)

----CONTRAINDICATIONS----

Hypersensitivity to lopinavir and ritonavir (e.g., toxic

epidermal necrolysis, Stevens-Johnson syndrome

erythema multiforme, urticaria, angioedema) or any of

2.3 Dosage Recommendations in Adults
2.4 Dosage Recommendations in Pediatric Patients 2.5 Dosage Recommendations in Pregnancy 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS

age of at least 14 days has been attained (2.4, 5.2)

5.1 Risk of Serious Adverse Reactions Due to Drug 5.2 Toxicity in Preterm Neonates 5.3 Pancreatitis 5.4 Hepatotoxicity5.5 QT Interval Prolongation

5.6 PR Interval Prolongation Diabetes Mellitus/Hyperglycemia 5.8 Immune Reconstitution Syndrome 5.9 Lipid Elevations 5.11 Patients with Hemophilia 5.12 Resistance/Cross-resistance

6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Potential for Lopinavir and Ritonavir to Affect Other

7.2 Potential for Other Drugs to Affect Lopinavir **FULL PRESCRIBING INFORMATION** 1 INDICATIONS AND USAGE

7.3 Established and Other Potentially Significant Drug Interactions
7.4 Drugs with No Observed or Predicted Interactions with Lopinavir and Ritonavir USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation
8.3 Females and Males of Reproductive Potential

8.5 Geriatric Use 8.6 Hepatic Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 12.4 Microbiology

8.4 Pediatric Use

information are not listed.

13 NOCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Adult Patients without Prior Antiretroviral Therapy

14.2 Adult Patients with Prior Antiretroviral Therapy 14.3 Other Studies Supporting Approval in Adult Patients 14.4 Pediatric Studies 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION

Lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults Limitations of Use: Genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir. The number

of baseline lopinavir Microbiology (12.4)]. 2 DOSAGE AND ADMINISTRATION 2.1 General Administration Recommendation Lopinavir and ritonavir tablets may be taken with or without food. The tablets should be swallowed whole and not chewed, broken, or crushed. Lopinavir and ritonavir oral solution must be taken with food. 2.3 Dosage Recommendations in Adults

Lopinavir and ritonavir can be given in once daily or twice daily dosing regimen at dosages noted in Tables 1 and 2. Lopinavir and ritonavir once daily dosing regimen is not recommended in: Adult patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V [see Microbiology (12.4)]. In combination with carbamazepine, phenobarbital, or phenytoin [see Drug Interactions (7.3)] In combination with eflavirenz, nevirapine, or nelfinavir [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].

In pediatric patients younger than 18 years of age [see Dosage and Administration (2.4)].

In pregnant women [see Dosage and Administration (2.5), Use in Specific Populations (8.1) and Clinical Pharmacology (12.3)]. Table 1. Recommended Dosage in Adults - Lopinavir and Ritonavir Once Daily Regimen Lopinavir and Ritonavir Dosage Form

Recommended Dosage 200 mg/50 mg Tablets 800 mg/200 mg (4 tablets) once daily 80 mg/20 mg per mL Oral Solution 800 mg/200 mg (10 mL) once daily Table 2. Recommended Dosage in Adults - Lopinavir and Ritonavir Twice Daily Regimen Lopinavir and Ritonavir Dosage Form Recommended Dosage 400 mg/100 mg (2 tablets) twice daily 200 mg/50 mg Tablets 80 mg/20 mg per mL Oral Solution 400 mg/100 mg (5 mL) twice daily

The dose of lopinavir and ritonavir must be increased when administered in combination with efavirenz, nevirapine or nelfinavir Table 3 outlines the dosage recommendations for twice daily dosing when lopinavir and ritonavir is taken in combination with Table 3. Recomm nded Dosage in Adults - Lopinavir and Ritonavir Twice Daily Regimen in Combination with Efavirenz, Nevirapine, or Nelfinavi Lopinavir and Ritonavir Dosage Form Recommended Dosage 500 mg/125 mg (2 tablets of 200 mg/50 mg 200 mg/50 mg Tablets and 100 mg/25 mg Tablets

80 mg/20 mg per mL Oral Solution 520 mg/130 mg (6.5 mL) twice daily 2.4 Dosage Recommendations in Pediatric Patients Lopinavir and ritonavir tablets and oral solution are not recommended for once daily dosing in pediatric patients younger than 18 years of age. The dose of the oral solution should be administered using the calibrated cup (supplied) or oral dosing sy Lopinavir and ritonavir 100/25 mg tablets should be considered only in children who have reliably demonstrated the ability to swallow the intact tablet. Lopinavir and ritonavir oral solution is not recommended in neonates before a postmenstrual age (first day of the mother's last menstrual period to birth plus the time elapsed after birth) of 42 weeks and a postnatal age of at least 14 days has been attained [see Warnings and Precautions (5.2)]. Lopinavir and ritonavir oral solution contains approximately 42% (v/v) ethanol and approximately 15% (w/v) propylene glycol. Total amounts of ethanol and propylene glycol from all medicines that are to be given to pediatric patients 14 days to 6 months

of age should be taken into account in order to avoid toxicity from these excipients [see Warnings and Precautions (5.2) and Pediatric Dosage Calculations surface area (BSA) to avoid underdosing or exceeding the recommended adult dose

Calculate the appropriate dose of lopinavir and ritonavir for each individual pediatric patient based on body weight (kg) or body Body surface area (BSA) can be calculated as follows: Ht (Cm) x Wt (kg) • BSA (m²) = 1

Patient Weight (kg) × Prescribed Iopinavir dose (mg/kg) = Administered Iopinavir dose (mg) Patient BSA (m²) × Prescribed lopinavir dose (mg/m²) = Administered lopinavir dose (mg) If lopinavir and ritonavir oral solution is used, the volume (mL) of lopinavir and ritonavir solution can be determined as follows: Volume of lopinavir and ritonavir solution (mL) = Administered lopinavir dose (mg) ÷ 80 (mg/mL)

The lopinavir and ritonavir dose can be calculated based on weight or BSA

Oral Solution Dosage Recommendation in Pediatric Patients 14 Days to Less Than 18 Years: Table 4 summarizes the recommended daily dosing regimen for pediatric patients 14 days to less than 18 years of age using Lopinavir and ritonavir administered in combination with efavirenz, nevirapine, or nelfinavir in patients younger than 6 months of age is not recommended. Total dose of lopinavir and ritonavir oral solution in pediatric patients should not exceed the ended adult daily dose of 400/100 mg (5mL) twice daily.

Table 4. Lopinavir and Ritonavir Oral Solution Daily Dosage Recommendations in Pediatric Patients 14 days to Less Than 18 Years Without Concomitant Efavirenz, Nevirapine, or Nelfinavir Based on BSA **Based on Weight** Frequency (mg/m²) (mg/kg) 14 days to 6 months 300/75 daily Less than 15 kg 12/3 Given twice Older than 6 months to less than 18 years 230/57.5 10/2.5 15 kg to 40 kg Tablet Dosage Recommendation in Pediatric Patients Older than 6 Months to Less than 18 Years:

Table 5 provides the dosing recommendations for pediatric patients older than 6 months to less than 18 years of age based on body weight or body surface area for lopinavir and ritonavir tablets. Table 5. Lopinavir and Ritonavir Tablet Daily Dosage Recommendations in Pediatric Patients > 6 Months to < 18 Years of Age Without Concomitant Efavirenz, Nevirapine, or Nelfinavir Body Weight (kg) Body Surface Area (m²)* Recommended number of 100/25 mg Tablets Twice Daily ≥0.6 to < 0.9 ≥15 to 25 >25 to 35 ≥0.9 to < 1.4 >35 ≥1.4 Lopinavir and ritonavir oral solution is available for children with a BSA less than 0.6 m² or those who are unable to reliably swallow a tablet.

Concomitant Therapy: Efavirenz, Nevirapine, or Nelfinavir ns using oral solution Table 6 provides the dosing recommendations for pediatric patients older than 6 months to less than 18 years of age based on body weight or body surface area for Lopinavir and Ritonavir Oral Solution when given in combination with efavirenz, nevirapine, dations for Pediatric Patients >6 Months to < 18 Based on Weight Based on BSA

Table 6. Lopinavir and Ritonavir Oral Solution Daily Dosage Recomme Years of Age With Concomitant Efavirenz, Nevirapine, or Nelfinavir Patient Age Frequency (mg/kg) (mg/m²) Given twice daily ≥15 kg to 45 kg 11/2.75 Table 7 provides the dosing recommendations for pediatric patients older than 6 months to less than 18 years of age based on body weight or body surface area for lopinavir and ritonavir tablets when given in combination with efavirenz, nevirapine, or nelfinavir. $Table \ 7. \ Lopinavir \ and \ Ritonavir \ Tablet \ Daily \ Dosage \ Recommendations \ for \ Pediatric \ Patients > 6 \ Months \ to < 18 \ Years$ of Age With Concomitant Efavirenz†, Nevirapine, or Nelfinavir Body Weight (kg) Body Surface Area (m²)* Recommended number of 100/25 mg Tablets Twice Daily ≥15 to 20 ≥ 0.6 to < 0.8>20 to 30 ≥0.8 to < 1.2 >30 to 45 ≥1.2 to <1.7 >45 ≥1.7 5 [see Dosage and Administration (2.4)]

†Please refer to the individual product labels for appropriate dosing in children Administer 400/100 mg of lopinavir and ritonavir twice daily in pregnant patients with no documented lopinavir-associated Once daily lopinavir and ritonavir dosing is not recommended in pregnancy [see Use in Specific Populations (8.1) and

Lopinavir and ritonavir oral solution is available for children with a BSA less than 0.6 m² or those who are unable to reliably

No dosage adjustment of lopinavir and ritonavir is required for patients during the postpartum period Lopinavir and Ritonavir Tablets USP, 200 mg/50 mg: Yellow colored, film coated oval shaped biconvex tablets debossed with LA58" on one side and plain on other side.

Lopinavir and Ritonavir Tablets USP, 100 mg/25 mg: Yellow colored, film coated oval shaped biconvex tablets debossed with 4 CONTRAINDICATIONS (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, urticaria, angioedema) to any of

tes ingredients, including ritonavir.

Lopinavir and ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Alpha 1- Adrenoreceptor Antagonist: alfuzosin

Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride

Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatir Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide PDE5 Inhibitor: sildenafii (Revatio*) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam

Lopinavir and ritonavir is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavi plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. Anticancer Agents: apalutamide

Antimycobacterial: rifampin
Herbal Products: St. John's Wort (hypericum perforatum) WARNINGS AND PRECAUTIONS

5.1 Risk of Serious Adverse Reactions Due to Drug Interactions Initiation of lopinavir and ritonavir, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving lopinavir and ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease entrations of lopinavir and ritonavir, respectively. These interactions may lead to: Clinically significant adverse reactions, potentially leading to severe, life-threatening, or fatal events from greater exposures of concomitant medications.

Clinically significant adverse reactions from greater exposures of lopinavir and ritonavir.

Loss of therapeutic effect of lopinavir and ritonavir and possible development of resistance See Table 12 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations [see Drug Interactions (7)]. Consider the potential for drug interactions prior to and during lopinavir and ritonavir therapy; review concomitant medications during lopinavir and ritonavir therapy, and monitor for the adverse reactions associated with the concomitant medications [see Contraindications (4) and Drug Interactions (7)].

5.2 Toxicity in Preterm Neonates Lopinavir and ritonavir oral solution contains the excipients ethanol, approximately 42% (v/v) and propylene glycol, approximately 15% (w/v). When administered concomitantly with propylene glycol, ethanol competitively inhibits the metabolism of propylene glycol, which may lead to elevated concentrations. Preterm neonates may be at increased risk of propylene glycol-associated adverse events due to diminished ability to metabolize propylene glycol, thereby leading to accumulation and potential adverse events. Postmarketing life-threatening cases of cardiac toxicity (including complete AV block, bradycardia, and cardiomyopathy) lactic acidosis, acute renal failure, CNS depression and respiratory complications leading to death have been reported, predominantly in preterm neonates receiving lopinavir and ritonavir oral solution.

Lopinavir and ritonavir oral solution should not be used in preterm neonates in the immediate postnatal period because of possible toxicities. A safe and effective dose of lopinavir and ritonavir oral solution in this patient population has not been established. However, if the benefit of using lopinavir and ritonavir oral solution to treat HIV infection in infants immediately after birth outweighs the potential risks, infants should be monitored closely for increases in serum osmolality and serum creatinine. and for toxicity related to lopinavir and ritonavir oral solution including: hyperosmolality, with or without lactic acidosis, renal toxicity, CNS depression (including stupor, coma, and apnea), seizures, hypotonia, cardiac arrhythmias and ECG changes, and hemolysis. Total amounts of ethanol and propylene glycol from all medicines that are to be given to infants should be taken into account in order to avoid toxicity from these excipients [see Dosage and Administration (2.4) and Overdosage (10)].

Pancreatitis has been observed in patients receiving lopinavir and ritonavir therapy, including those who developed marked triglyceride elevations. In some cases, fatalities have been observed. Although a causal relationship to lopinavir and ritonavi has not been established, marked triglyceride elevations are a risk factor for development of pancreatitis [see Warnings and Precautions (5.9)]. Patients with advanced HIV-1 disease may be at increased risk of elevated triglycerides and pancreatitis, and patients with a history of pancreatitis may be at increased risk for recurrence during lopinavir and ritonavir therapy. Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis occur. Patients who exhibit these signs or symptoms should be evaluated and lopinavir and ritonavir and/or other antiretroviral therapy should be suspended as clinically appropriate

Patients with underlying hepatitis B or C or marked elevations in transaminase prior to treatment may be at increased risk for developing or worsening of transaminase elevations or hepatic decompensation with use of lopinavir and ritonavir There have been postmarketing reports of hepatic dysfunction, including some fatalities. These have generally occurred in patients with advanced HIV-1 disease taking multiple concomitant medications in the setting of underlying chronic hepatitis or cirrhosis. A causal relationship with lopinavir and ritonavir therapy has not been established. Elevated transaminases with or without elevated bilirubin levels have been reported in HIV-1 mono-infected and uninfected patients as early as 7 days after the initiation of lopinavir and ritonavir in conjunction with other antiretroviral agents. In some cases, the hepatic dysfunction was serious; however, a definitive causal relationship with lopinavir and ritonavir therapy has not

Appropriate laboratory testing should be conducted prior to initiating therapy with lopinavir and ritonavir and patients should be monitored closely during treatment. Increased AST/ALT monitoring should be considered in the patients with underlying chronic hepatitis or cirrhosis, especially during the first several months of lopinavir and ritonavir treatment [see Use in Specific Populations (8.6)]. 5.5 QT Interval Prolongation

Postmarketing cases of QT interval prolongation and torsade de pointes have been reported although causality of lopinavir and ritionavir could not be established. Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval [see Clinical Pharmacology (12.3)]. 5.6 PR Interval Prolongation onavir prolongs the PR interval in some patients. Cases of second or third degree atrioventricular block have been

reported. Lopinavir and ritonavir should be used with caution in patients with underlying structural heart disease, pre-existing conduction system abnormalities, ischemic heart disease or cardiomyopathies, as these patients may be at increased risk for The impact on the PR interval of co-administration of lopinavir and ritonavir with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. As a result, co-administration of lopinavir and ritonavir with these drugs should be undertaken with caution, particularly with those drugs

metabolized by CYP3A. Clinical monitoring is recommended [see Clinical Pharmacology (12.3)] 5.7 Diabetes Mellitus/Hyperglycemia New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, and hyperglycemia have been reported during postmarketing surveillance in HIV-1 infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship

between protease inhibitor therapy and these events has not been established. Consider monitoring for hyperglycemia, new onset diabetes mellitus or an exacerbation of diabetes mellitus in patients treated with lopinavir and ritonavi Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including lopinavir and ritonavir. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection

cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis) which may necessitate further evaluation and Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation

Treatment with lopinavir and ritonavir has resulted in large increases in the concentration of total cholesterol and triglycerides therapy and at periodic intervals during therapy. Lipid disorders should be managed as clinically appropriate, taking into account any potential drug-drug interactions with lopinavir and ritonavir and HMG-CoA reductase inhibitors [see Contraindications (4) and Drug Interactions (7.3)]. *Sections or subsections omitted from the full prescribing 5.10 Fat Redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established. 5.11 Patients with Hemophilia d bleeding, including spontaneous skin hematomas and hemarthrosis have been reported in patients with hemophilia type A and B treated with protease inhibitors. In some patients additional factor VIII was given. In more than half of the reported

ases, treatment with protease inhibitors was continued or reintroduced. A causal relationship between protease inhibitor therapy and these events has not been established. 5.12 Resistance/Cross-resistance Because the potential for HIV cross-resistance among protease inhibitors has not been fully explored in lopinavir and ritonavir-

treated patients, it is unknown what effect therapy with lopinavir and ritonavir will have on the activity of subsequence protease inhibitors [see Microbiology (12.4)]. 6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling. QT Interval Prolongation, PR Interval Prolongation [see Warnings and Precautions (5.5, 5.6)] Drug Interactions [see Warnings and Precautions (5.1)]

Pancreatitis [see Warnings and Precautions (5.3)] Hepatotoxicity [see Warnings and Precautions (5.4)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clir practice.

Adverse Reactions in Adults The safety of lopinavir and ritonavir has been investigated in about 2,600 patients in Phase II to IV clinical trials, of which about 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily. Along with nucleoside reverse transcriptase inhibitors (NRTIs), in some studies, lopinavir and ritonavir was used in combination with efavirenz or nevirapine. In clinical studies the incidence of diarrhea in patients treated with either lopinavir and ritonavir capsules or tablets was greater in those patients treated once daily than in those patients treated twice daily. Any grade of diarrhea was reported by at least half of patients taking once daily lopinavir and ritonavir capsules or tablets. At the time of treatment discontinuation, 4.2 to 6.3% of patients taking once daily lopinavir and ritonavir and 1.8 to 3.7% of those taking twice daily lopinavir and ritonavir reported ongoing diarrhea.

Commonly reported adverse reactions to lopinavir and ritonavir included diarrhea, nausea, vomiting, hypertriglyceridemia and hypercholesterolemia. Diarrhea, nausea and vomiting may occur at the beginning of the treatment while hypertriglyceridemia and hypercholesterolemia may occur later. The following have been identified as adverse reactions of moderate or severe intensity (Table 8):

Table 8. Adverse Reactions of Moderate or Severe Intensity Occurring in at Least 0.1% of Adult Patients Receiving Lopinavir and Ritonavir in Combined Phase II/IV Studies (N=2,612) System Organ Class (SOC) and Adverse Reaction BLOOD AND LYMPHATIC SYSTEM DISORDERS anemia* 54 2.1 1.7 leukopenia and neutropenia 44 1.3 lymphadenopathy* CARDIAC DISORDERS atherosclerosis such as myocardial infarction* 0.4 0.1 atrioventricular block* 0.1 tricuspid valve incompetence **EAR AND LABYRINTH DISORDERS** 0.3 0.2 **ENDOCRINE DISORDERS** hypogonadism' 16 0.8^{1} **EYE DISORDERS** 0.3 visual impairment GASTROINTESTINAL DISORDERS 510 19.5 10.3 269 nausea vomiting* 177 6.8 abdominal pain (upper and lower) $\!\!\!\!\!^\star$ 160 6.1 gastroenteritis and colitis* 2.5 dyspepsia 53 2 1.7 pancreatitis* 45 Gastroesophageal Reflux Disease (GERD)* hemorrhoids 39 1.5 1.4 36 abdominal distension 1.3 constipation* 26 stomatitis and oral ulcers* 24 0.9 duodenitis and gastritis' 0.8 gastrointestinal hemorrhage including rectal hemorrhage' 0.5 dry mouth 0.3 gastrointestinal ulcer* 0.2 0.2 fecal incontinence GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS fatigue including asthenia 198 7.6 HEPATOBILIARY DISORDERS hepatitis including AST, ALT, and GGT increases* 3.5 hepatomegaly 0.2 0.1 cholangitis 0.1 hepatic steatosis **IMMUNE SYSTEM DISORDERS** hypersensitivity including urticaria and angioedema' immune reconstitution syndrome 0.1 INFECTIONS AND INFESTATIONS upper respiratory tract infection* 363 13.9 lower respiratory tract infection' 202 7.7 skin infections including cellulitis, folliculitis, and furuncle* 3.3 METABOLISM AND NUTRITION DISORDERS hypercholesterolemia* 192 7.4 161 6.2 weight decreased* 2.3 decreased appetite 52 2 blood glucose disorders including diabetes mellitus* 30 1.1 weight increased 0.4 lactic acidosis* MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS musculoskeletal pain including arthralgia and back pain 6.4 46 1.8 muscle disorders such as weakness and spasms 1.3 0.7 rhabdomyolysis* osteonecrosis 0.1 **NERVOUS SYSTEM DISORDERS** headache including migraine 165 6.3 insomnia* 99 3.8 neuropathy and peripheral neuropathy 51 2 dizziness 0.7 ageusia* 19 convulsion* 0.3 tremor* 0.3 0.2 cerebral vascular event PSYCHIATRIC DISORDERS anxiety* 101 3.9 0.7 abnormal dream 0.7 libido decreased **RENAL AND URINARY DISORDERS** hematuria* 0.8 20 nephritis* 0.1

¹ Percentage of male population (N=2,038) ² Percentage of female population (N=574) Laboratory Abnormalities in Adults The percentages of adult patients treated with combination therapy with Grade 3 to 4 laboratory abnormalities are presented in Table 9 (treatment-naïve patients) and Table 10 (treatment- experienced Table 9. Grade 3 to 4 Laboratory Abnormalities Reported in ≥ 2% of Adult Antiretroviral-Naïve Patients Study 863 Study 730 (360 Weeks) Lopinavir

phenobarbital,

phenytoin

*Represents a medical concept including several similar MedDRA PTs

Nelfinavir Lopinavir Lopinavir and Ritonavii 750 mg Three Limit1 Times Daily + d4T + 3TC Variable Once Daily + TDF + FTC + TDF + FTC Twice Daily -Daily + d4T + 3TC d4T + 3TC(N = 100) (N = 327)(N=333) (N=331)(N = 326)Chemistry High Glucose > 250 mg/dL 2% 2% 4% 0% <1% Uric Acid > 12 mg/dL 2% 2% 5% <1% 1% SGOT/AST2 > 180 U/L 4% 10% 1% 2% SGPT/ ALT2 >215 U/L 4% 11% 4% 1% 1% IGGT >300 U/L N/A N/A 10% N/A N/A Total Choles >300 mg/dL 9% 27% 4% 3% 5% >750 mg/dL 9% 1% 29% 6% 3% Triglycerides Amylase >2 x ULN 3% 2% 4% N/A N/A >2 x ULN N/A N/A N/A 3% 5% Chemistry Low Calculated <50 mL/min N/A N/A N/A 2% 2% Clearance Low Hematology <0.75 x 10⁹/L 1% 5% 2% 1% 1 ULN = upper limit of the normal range; N/A = Not Applicable Criterion for Study 730 was >5x ULN (AST/ALT). Table 10. Grade 3 to 4 Laboratory Abnormalities Reported in ≥ 2% of Adult Protease Inhibitor-Experienced Patients

		Study 888 (48 Weeks)		Study 957 ² and Study 765 ³ (84 to 144 Weeks)	Study 802 (48 Weeks)	
Variable	Limit ¹	Lopinavir and Ritonavir 400/100 mg Twice Daily + NVP + NRTIs (N = 148)	Investigator- Selected Protease Inhibitor(s) + NVP + NRTIs (N = 140)	Lopinavir and Ritonavir Twice Daily + NNRTI + NRTIs (N = 127)	Lopinavir and Ritonavir 800/200 mg Once Daily + NRTIs (N=300)	Lopinavir and Ritonavir 400/100 mg Twice Daily + NRTIs (N=299)
Chemistry	High					
Glucose	>250 mg/dL	1%	2%	5%	2%	2%
Total Bilirubin	>3.48 mg/dL	1%	3%	1%	1%	1%
SGOT/AST⁴	>180 U/L	5%	11%	8%	3%	2%
SGPT/ALT⁴	>215 U/L	6%	13%	10%	2%	2%
GGT	>300 U/L	N/A	N/A	29%	N/A	N/A
Total Cholesterol	>300 mg/dL	20%	21%	39%	6%	7%
Triglycerides	>750 mg/dL	25%	21%	36%	5%	6%
Amylase	>2 x ULN	4%	8%	8%	4%	4%
Lipase	>2 x ULN	N/A	N/A	N/A	4%	1%
Creatine Phosphokinase	>4 x ULN	N/A	N/A	N/A	4%	5%
Chemistry	Low					
Calculated Creatinine Clearance	<50 mL/min	N/A	N/A	N/A	3%	3%
Inorganic Phosphorus	<1.5 mg/dL	1%	0%	2%	1%	<1%
Hematology	Low					
Neutrophils	<0.75 x 10 ⁹ /L	1%	2%	4%	3%	4%
Hemoglobin	<80 g/L	1%	1%	1%	1%	2%

for 84 weeks. Patients received lopinavir and ritonavir in combination with NRTIs and efavirenz Includes clinical laboratory data from patients receiving 400/100 mg twice daily (n = 36) or 400/200 mg twice daily (n = 34) for 144 weeks. Patients received lopinavir and ritonavir in combination with NRTIs and nevirapine Criterion for Study 802 was >5x ULN (AST/ALT). Adverse Reactions in Pediatric Patients Lopinavir and ritonavir oral solution dosed up to 300/75 mg/m² has been studied in 100 pediatric patients 6 months to 12 years of age. The adverse reaction profile seen during Study 940 was similar to that for adult patients. Dysgeusia (22%), vomiting (21%), and diarrhea (12%) were the most common adverse reactions of any severity reported in

pediatric patients treated with combination therapy for up to 48 weeks in Study 940. A total of 8 patients experienced adverse reactions of moderate to severe intensity. The adverse reactions meeting these criteria and reported for the 8 subjects include: hypersensitivity (characterized by fever, rash and jaundice), pyrexia, viral infection, constipation, hepatomegaly, pancreatitis, vomiting, alanine aminotransferase increased, dry skin, rash, and dysgeusia. Rash was the only event of those listed that occurred in 2 or more subjects (N = 3). opinavir and ritonavir oral solution dosed at 300/75 mg/m² has been studied in 31 pediatric patients 14 days to 6 months of age. The adverse reaction profile in Study 1030 was similar to that observed in older children and adults. No adverse reaction was reported in greater than 10% of subjects. Adverse drug reactions of moderate to severe intensity occurring in 2 or more subjects included decreased neutrophil count (N=3), anemia (N=2), high potassium (N=2), and low sodium (N=2).

Lopinavir and ritonavir oral solution and soft gelatin capsules dosed at higher than recommended doses including 400/100 mg/ m^2 (without concomitant NNRTI) and 480/120 mg/m^2 (with concomitant NNRTI) have been studied in 26 pediatric patients 7 to 18 years of age in Study 1038. Patients also had saquinavir mesylate added to their regimen at Week 4. Rash (12%), blood cholesterol abnormal (12%) and blood triglycerides abnormal (12%) were the only adverse reactions reported in greater than 10% of subjects. Adverse drug reactions of moderate to severe intensity occurring in 2 or more subjects included rash (N=3), blood triglycerides abnormal (N=3), and electrocardiogram QT prolonged (N=2). Both subjects with QT prolongation had additional predisposing conditions such as electrolyte abnormalities, concomitant medications, or preexisting cardiac abnormalities Laboratory Abnormalities in Pediatric Patients The percentages of pediatric patients treated with combination therapy including lopinavir and ritonavir with Grade 3 to 4 laboratory abnormalities are presented in Table 11.

Table 11. Grade 3 to 4 Laboratory Abno. nalities Reported in ≥ 2% Pediatric Patients in Study 940

/ariable	Limit ¹	Lopinavir and Ritonavir Twice Daily + RTIs (N = 100)
Chemistry	High	
Sodium	> 149 mEq/L	3%
Total Bilirubin	≥ 3.0 x ULN	3%
SGOT/AST	> 180 U/L	8%
SGPT/ALT	> 215 U/L	7%
Total Cholesterol	> 300 mg/dL	3%
Amylase	> 2.5 x ULN	7%²
Chemistry	Low	
Sodium	< 130 mEq/L	3%
Hematology	Low	
Platelet Count	< 50 x 10 ⁹ /L	4%
Neutrophils	< 0.40 x 10°/L	2%
ULN = upper limit of the normal range of ULN = upper limit of the normal range of the upper limit of the normal range of the upper limit of the up	ange. se confirmed by elevations in pancre	atic amylase.
.2 Postmarketing Experience		

The following adverse reactions have been reported during postmarketing use of lopinavir and ritonavir. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or establish a causal relationship to lopinavir and ritonavir exposure.

mulation of body fat has been reported [see Warnings and Precautions (5.10)]. Bradyarrhythmias. First-degree AV block, second-degree AV block, third-degree AV block, QTc interval prolongation, torsades

Renal and Urinary Disorders <u>Skin and Appendages</u> Toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome and erythema multiforme.

7 DRUG INTERACTIONS 7.1 Potential for Lopinavir and Ritonavir to Affect Other Drugs

Lopinavir/ritonavir is an inhibitor of CYP3A and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co-administered with lopinavir and ritonavir. Thus, co-administration of objections of any increases in AGC (Solid) when Caraministrated with opinative and ritonavir. This, Co-administration to opinative and ritonavir with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 12. Additionally, lopinavir and ritonavir induces glucuronidatio Published data suggest that lopinavir is an inhibitor of OATP1B1.

These examples are a guide and not considered a comprehensive list of all possible drugs that may interact with lopinavir/ navir. The healthcare provider should consult appropriate references for co 7.2 Potential for Other Drugs to Affect Lopinavir Lopinavir/ritonavir is a CYP3A substrate; therefore, drugs that induce CYP3A may decrease lopinavir plasma concentrations and reduce lopinavir and ritonavir's therapeutic effect. Although not observed in the lopinavir and ritonavir/ketoconazole drug interaction study, co-administration of lopinavir and ritonavir and other drugs that inhibit CYP3A may increase lopinavir plasma concentrations.

7.3 Established and Other Potentially Significant Drug Interactions Table 12 provides a listing of established or potentially clinically significant drug interactions. Alteration in dose or regimen may be recommended based on drug interaction studies or predicted interaction [see Contraindications (4), Warnings and Precautions (5.1). Clinical Pharmacology (12.3)] for magnitude of interaction

Concomitant Drug Class:	Effect on Concentration of	Clinical Comments
Drug Name	Lopinavir or Concomitant Drug	
	HIV-1 Antiviral	Agents
HIV-1 Protease Inhibitor:	↓ amprenavir	An increased rate of adverse reactions has been
fosamprenavir/ritonavir	↓ lopinavir	observed with co-administration of these medications. Appropriate doses of the combinations with respect to safety and efficacy have not been established.
HIV-1 Protease Inhibitor: indinavir*	↑ indinavir	Decrease indinavir dose to 600 mg twice daily, when co-administered with lopinavir and ritonavir 400/100 mg twice daily. Lopinavir and ritonavir once daily has not been studied in combination with indinavir.
HIV-1 Protease Inhibitor: nelfinavir*	↑ nelfinavir ↑ M8 metabolite of nelfinavir ↓ lopinavir	Lopinavir and ritonavir once daily in combination with nelfinavir is not recommended [see Dosage and Administration (2)].
HIV-1 Protease Inhibitor: ritonavir*	↑ lopinavir	Appropriate doses of additional ritonavir in combination with lopinavir and ritonavir with respect to safety and efficacy have not been established.
HIV-1 Protease Inhibitor: saquinavir	↑ saquinavir	The saquinavir dose is 1,000 mg twice daily, when co-administered with lopinavir and ritonavir 400/100 mg twice daily. Lopinavir and ritonavir once daily has not been studied in combination with saquinavir.
HIV-1 Protease Inhibitor: tipranavir*	↓ lopinavir	Co-administration with tipranavir (500 mg twice daily) and ritonavir (200 mg twice daily) is not recommended.
HIV CCR5 – Antagonist: maraviroc*	↑ maraviroc	When co-administered, patients should receive 150 mg twice daily of maraviroc. For further details see complete prescribing information for maraviroc.
Non-nucleoside Reverse Transcriptase Inhibitors: efavirenz*, nevirapine*	↓ lopinavir	Increase the dose of lopinavir and ritonavir tablets to 500/125 mg when lopinavir and ritonavir tablet is co-administered with efavirenz or nevirapine. Lopinavir and ritonavir once daily in combination with efavirenz or nevirapine is not recommended [see Dosage and Administration (2)].
Non-nucleoside Reverse	↑ lopinavir	Appropriate doses of the combination with respect to
Transcriptase Inhibitor: delavirdine		safety and efficacy have not been established.
Nucleoside Reverse Transcriptase Inhibitor: didanosine		Lopinavir and ritonavir tablets can be administered simultaneously with didanosine without food. For lopinavir and ritonavir oral solution, it is recommended that didanosine be administered on an empty stomach; therefore, didanosine should be
Nucleoside Deverse Transminters	A town for the	given one hour before or two hours after lopinavir and ritonavir oral solution (given with food).
Nucleoside Reverse Transcriptase Inhibitor: tenofovir disoproxil fumarate*	↑ tenofovir	Patients receiving lopinavir and ritonavir and tenofovir should be monitored for adverse reactions associated with tenofovir.
Nucleoside Reverse Transcriptase Inhibitors: abacavir zidovudine	↓ abacavir ↓ zidovudine	The clinical significance of this potential interaction is unknown.
	Other Agen	nts
Alpha 1- Adrenoreceptor Antagonist: alfuzosin	↑ alfuzosin	Contraindicated due to potential hypotension [see Contraindications (4)].
Antianginal: ranolazine	↑ ranolazine	Contraindicated due to potential for serious and/or life-threatening reactions [see Contraindications (4)].
Antiarrhythmics: dronedarone	↑ dronedarone	Contraindicated due to potential for cardiac arrhythmias [see Contraindications (4)].
Antiarrhythmics e.g. amiodarone, bepridil, lidocaine (systemic), quinidine	↑ antiarrhythmics	Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered with lopinavir and ritonavir.
Anticancer Agents: abemaciclib, apalutamide, encorafenib,	↑ anticancer agents ↓lopinavir/ritonavir*	Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to lopinavir and ritonavir or to the class of protease inhibitors [see Contraindications (4)].
ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine		Avoid co-administration of encorafenib or ivosidenib with lopinavir and ritonavir due to potential risk of serious adverse events such as QT interval prolongation. If co-administration of encorafenib with lopinavir and ritonavir cannot be avoided, modify dose as recommended in encorafenib USPI. If co-administration of ivosidenib with lopinavir and ritonavir cannot be avoided, reduce ivosidenib dose to 250 mg once daily.
		Avoid use of neratinib, venetoclax or ibrutinib with lopinavir and ritonavir.
		For vincristine and vinblastine, consideration should be given to temporarily withholding the ritonavir-containing antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects when longinger and ritonavir is administered concurrently with

		In addition, co-administration of phenytoin and lopinavir and ritonavir may cause decreases in steady-state phenytoin concentrations. Phenytoin levels should be monitored when co-administering with lopinavir and ritonavir.
Anticonvulsants: lamotrigine, valproate	↓ lamotrigine ↓ or ↔ valproate	A dose increase of lamotrigine or valproate may be needed when co-administered with lopinavir and ritonavir and therapeutic concentration monitoring for lamotrigine may be indicated; particularly during dosagradjustments.
Antidepressant: bupropion	↓ bupropion ↓ active metabolite,	Patients receiving lopinavir and ritonavir and bupropion concurrently should be monitored for an adequate
Antidepressant: trazodone	hydroxybupropion ↑ trazodone	clinical response to bupropion. Adverse reactions of nausea, dizziness, hypotension and syncope have been observed following co-
Anti-infective: clarithromycin	↑ clarithromycin	administration of trazodone and ritonavir. A lower dose of trazodone should be considered. For patients with renal impairment, adjust clarithromycir
The missians of the state of th	, sammennyem	dose as follows: For patients on lopinavir and ritonavir with CL _{ca} 30 to 60 mL/min the dose of clarithromycin should be
		reduced by 50%. For patients on lopinavir and ritonavir with CL _{CR} < 30 mL/min the dose of clarithromycin should be
		decreased by 75%. No dose adjustment for patients with normal renal
Antifungals: ketoconazole*, itraconazole, voriconazole	↑ ketoconazole ↑ itraconazole	function is necessary. High doses of ketoconazole (>200 mg/day) or itraconazole (> 200 mg/day) are not recommended.
isavuconazonium sulfate*	↓ voriconazole ↑ isavuconazonium	The coadministration of voriconazole and lopinavir and ritonavir should be avoided unless an assessment of the benefit/risk to the patient justifies the use of
		voriconazole. Isavuconazonium and lopinavir and ritonavir should be coadministered with caution. Alternative antifungal therapies should be considered in
Anti-gout: colchicine	↑ colchicine	these patients. Contraindicated due to potential for serious and/or
		life-threatening reactions in patients with renal and/or hepatic impairment [see Contraindications (4)]. For patients with normal renal or hepatic function:
		Treatment of gout flares-co-administration of colchicine in patients on lopinavir and ritonavir: 0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half
		tablet) 1 hour later. Dose to be repeated no earlier than 3 days. Prophylaxis of gout flares-co-administration of
		colchicine in patients on lopinavir and ritonavir: If the original colchicine regimen was 0.6 mg twice a day the regimen should be adjusted to 0.3 mg once a day.
		If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.
		Treatment of familial Mediterranean fever (FMF)-co- administration of colchicine in patients on lopinavir and
		ritonavir: Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).
Antimycobacterial: rifampin	↓ lopinavir	Contraindicated due to potential loss of virologic response and possible resistance to lopinavir and ritonavir or to the class of protease inhibitors or
		other co-administered antiretroviral agents [see Contraindications (4)].
Antimycobacterial: bedaquiline	↑ bedaquiline	Bedaquiline should only be used with lopinavir and ritonavir if the benefit of co-administration outweighs the risk.
Antimycobacterial: rifabutin*	↑ rifabutin and rifabutin metabolite	Dosage reduction of rifabutin by at least 75% of the usual dose of 300 mg/day is recommended (i.e., a maximum dose of 150 mg every other day or three
		times per week). Increased monitoring for adverse reactions is warranted in patients receiving the combination. Further dosage reduction of rifabutin may
Antiparasitic: atovaquone	↓ atovaquone	be necessary. Clinical significance is unknown; however, increase in
Antipsychotics: lurasidone	↑ lurasidone	atovaquone doses may be needed. Contraindicated due to potential for serious and/or life-threatening reactions [see Contraindications (4)].
pimozide	↑ pimozide	Contraindicated due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias [see Contraindications (4)].
primozide Antipsychotics: quetiapine	↑ quetiapine	Initiation of lopinavir and ritonavir in patients taking quetiapine:
		Consider alternative antiretroviral therapy to avoid increases in quetiapine exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated.
		current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.
		monitoring. Initiation of quetiapine in patients taking lopinavir and ritonavir:
Contraceptive:	↓ ethinyl estradiol	Refer to the quetiapine prescribing information for initia dosing and titration of quetiapine. Because contraceptive steroid concentrations may be
ethinyl estradiol*	V Strainly College	altered when lopinavir and ritonavir is co- administered with oral contraceptives or with the contraceptive patch alternative methods of nonhormonal contraception are
Dihydropyridine Calcium	↑ dihydropyridine	recommended. Clinical monitoring of patients is recommended and a
Channel Blockers: e.g. felodipine, nifedipine,	calcium channel blockers	dose reduction of the dihydropyridine calcium channel blocker may be considered.
nicardipine Disulfiram/metronidazole		Lopinavir and ritonavir oral solution contains ethanol, which can produce disulfiram-like reactions when co-
Endothelin Receptor Antagonists:	↑ bosentan	administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole). Co-administration of bosentan in patients on lopinavir
bosentan	Dosentari	and ritonavir: In patients who have been receiving lopinavir and ritonavir for at least 10 days, start bosentan at 62.5 mg
		once daily or every other day based upon individual tolerability.
		Co-administration of lopinavir and ritonavir in patients on bosentan: Discontinue use of bosentan at least 36 hours prior to
		initiation of lopinavir and ritonavir. After at least 10 days following the initiation of lopinavir and ritonavir, resume bosentan at 62.5 mg
Ergot Derivatives:	↑ ergot derivatives	once daily or every other day based upon individual tolerability. Contraindicated due to potential for acute ergot toxicity
dihydroergotamine, ergotamine, methylergonovine		characterized by peripheral vasospasm and ischemia of the extremities and other tissues [see Contraindications (4)].
GI Motility Agent: cisapride GnRH Receptor Antagonists:	↑ cisapride ↑ elagolix	Contraindicated due to potential for cardiac arrhythmias [see Contraindications (4)]. Concomitant use of elagolix 200 mg twice daily and
elagolix	↓ lopinavir/ritonavir	lopinavir and ritonavir for more than 1 month is not recommended due to potential risk of adverse events such as bone loss and hepatic transaminase elevations
	↑ elbasvir/grazoprevir	Limit concomitant use of elagolix 150 mg once daily and lopinavir and ritonavir to 6 months.
Hepatitis C direct acting antiviral: elbasvir/grazoprevir Hepatitis C direct acting antivirals:	↓ lopinavir	Contraindicated due to increased risk of alanine transaminase (ALT) elevations [see Contraindications (4)] It is not recommended to co-administer lopinavir and
boceprevir* glecaprevir/Pibrentasvir 	↓ boceprevir ↓ ritonavir ↑ glecaprevir	ritonavir and boceprevir, glecaprevir/pibrentasvir, simeprevir, sofosbuvir/velpatasvir/voxilaprevir, or ombitasvir/paritaprevir/ritonavir and dasabuvir.
simeprevir sofosbuvir/velpatasvir/voxilaprevir	↑ pibrentasvir ↑ simeprevir ↑ sofosbuvir	
ombitasvir/paritaprevir/ ritonavir and dasabuvir*	↑ velpatasvir ↑ voxilaprevir ↑ ombitasvir	
Jasabuvii	↑ paritaprevir ↑ ritonavir ↔ dasabuvir	
Herbal Products: St. John's Wort (hypericum	↓ lopinavir	Contraindicated due to potential for loss of virologic response and possible resistance to lopinavir and ritonavir or to the class of protease
perforatum) Lipid-modifying agents		lopinavir and ritonavir or to the class of protease inhibitors [see Contraindications (4)].
HMG-CoA Reductase Inhibitors: lovastatin simvastatin	↑ lovastatin ↑ simvastatin	Contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications (4)].
atorvastatin rosuvastatin	↑ atorvastatin ↑ rosuvastatin	Use atorvastatin with caution and at the lowest necessary dose. Titrate rosuvastatin dose carefully
Microsomal triglyceride transfer	↑ lomitapide	and use the lowest necessary dose; do not exceed rosuvastatin 10 mg/day. Lomitapide is a sensitive substrate for CYP3A4
protein (MTTP) Inhibitor:		metabolism. CYP3A4 inhibitors increase the exposure of lomitapide, with strong inhibitors increasing exposure approximately 27-fold.
		Concomitant use of moderate or strong CYP3A4 inhibitors with lomitapide is contraindicated due to potential for hepatotoxicity [see Contraindications (4)].
Immunosuppressants: e.g. cyclosporine, tacrolimus,	↑ immunosuppressants	Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with lopinavir and ritonavir.
sirolimus Kinase Inhibitors:	↑ fostamatinib	Monitor for toxicities of R406 such as hepatotoxicity
fostamatinib (also see anticancer agents above) Long-acting beta-adrenoceptor	metabolite R406 ↑ salmeterol	and neutropenia. Fostamatinib dose reduction may be required. Concurrent administration of salmeterol and lopinavir
Agonist: salmeterol		and ritonavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT
Narcotic Analgesics: methadone,*	↓ methadone ↑ fentanyl	prolongation, palpitations and sinus tachyoardia. Dosage of methadone may need to be increased when co-administered with lopinavir and ritonavir.
o narryi	, Tornearly!	co-administered with lopinavir and ritonavir. Careful monitoring of therapeutic and adverse effects (including potentially fatal respiratory depression)
		is recommended when fentanyl is concomitantly administered with lopinavir and ritonavir.
PDE5 inhibitors: avanafil, sildenafil, adalafil,	↑ avanafil ↑ sildenafil ↑ tadalafil	Sildenafil when used for the treatment of pulmonary arterial hypertension (Revatio®) is contraindicated due to the potential for sildenafil-associated adverse events
vardenafil	↑ vardenafil	including visual abnormalities, hypotension, prolonged erection, and syncope [see Contraindications(4)]. Do not use lopinavir and ritonavir with avanafil because
		a safe and effective avanafil dosage regimen has not been established.
		Particular caution should be used when prescribing sildenafil, tadalafil, or vardenafil in patients receiving lopinavir and ritonavir. Co-administration of lopinavir
		and ritonavir with these drugs may result in an increase in PDE5 inhibitor associated adverse reactions including hypothesion, syncope, visual changes and
		prolonged erection. Use of PDE5 inhibitors for pulmonary arterial hypertension (PAH):
		Sildenafil (Revatio®) is contraindicated [see Contraindications (4)].
		The following dose adjustments are recommended for use of tadalafil (Adcirca®) with lopinavir and ritonavir: Co-administration of ADCIRCA in patients on lopinavir
		and ritonavir: In patients receiving lopinavir and ritonavir for at least one week, start ADCIRCA at 20 mg once daily. Increase
		to 40 mg once daily based upon individual tolerability. Co-administration of lopinavir and ritonavir in patients
		on ADCIRCA: Avoid use of ADCIRCA during the initiation of lopinavir
		and ritonavir. Stop ADCIRCA at least 24 hours prior to
		and ritonavir. Stop ADCIRCA at least 24 hours prior to starting lopinavir and ritonavir. After at least one week following the initiation of lopinavir and ritonavir, resume ADCIRCA at 20 mg once daily. Increase to 40 mg once
		and ritonavir. Stop ADCIRCA at least 24 hours prior to starting lopinavir and ritonavir. After at least one week following the initiation of lopinavir and ritonavir, resume ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability. Use of PDE5 inhibitors for erectile dysfunction:
		and ritonavir. Stop ADCIRCA at least 24 hours prior to starting lopinavir and ritonavir. After at least one week following the initiation of lopinavir and ritonavir, resume ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability. Use of PDE5 inhibitors for erectile dysfunction: It is recommended not to exceed the following doses: Sildenafil: 25 mg every 48 hours Tadalafil: 10 mg every 72 hours
Sedative/Hypnotics: triazolam,	↑ triazolam ↑ midazolam	and ritonavir. Stop ADCIRCA at least 24 hours prior to starting lopinavir and ritonavir. After at least one week following the initiation of lopinavir and ritonavir, resume ADCIRCA at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability. Use of PDE5 inhibitors for erectile dysfunction: It is recommended not to exceed the following doses: Sidenafii: 25 mg every 48 hours

Lopinavir and ritonavir may be less effective due to

with caution.

recommended.

decreased lopinavir plasma concentrations in patients

taking these agents concomitantly and should be used

Lopinavir and ritonavir once daily in combination with

carbamazepine, phenobarbital, or phenytoin is not

refers to interaction with apalutamide. 7.4 Drugs with No Observed or Predicted Interactions with Lopinavir and RitonavirDrug interaction or clinical studies reveal no clinically significant interaction between lopinavir and ritonavir and desipramine (CYP2D6 probe), etravirine, pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. Based on known metabolic profiles, clinically significant drug interactions are not expected between lopinavir and ritonavir and lapsone, trimethoprim/sulfamethoxazole, azithromycin, erythromycin, or fluconazole

lopinavir

see Clinical Pharmacology (12.3) for magnitude of interaction

glucocorticoids

corticosteroids.

parenteral midazolam, close clinical monitoring for

systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and developr of resistance to lopinavir. Consider alternative

respiratory depression and/or prolonged sedation should be exercised and dosage adjustment should b

Coadministration with corticosteroids whose exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing's syndrome and

and prednisolone (whose PK and/or PD are less

affected by strong CYP3A inhibitors relative to other studied steroids) should be considered, particularly for

ritonavir

swallow a tablet.

• Inflammation of your pancreas (pancreatitis). Lopinavir and ritonavir can cause pancreatitis which may be serious and may lead to death. People who have high levels of a certain fat (triglycerides) have a risk for developing pancreatitis. If you have advanced HIV-1 disease, you may have an increased risk of high triglyceride levels in your blood, and pancreatitis. If you have an increased risk of high triglyceride levels in your blood, and pancreatitis. If you have an increased risk of it coming back again during treatment with lopinavir and ritonavir. Tell your healthcare provider if you have any signs or symptoms of pancreatitis including:

• Liver problems. Liver problems, including death, can happen in people who take lopinavir and ritonavir. Your healthcare provider should do blood tests before and during your treatment with lopinavir and ritonavir to check your liver function. If increased risk for developing new or workers. oblems, including death, can happen in people who take ur healthcare provider should do blood tests before and th lopinavir and ritonavir to check your liver function. If Hepatitis C, or other liver problems, you may have an ving new or worsening of liver problems during treatment vir. Tell your healthcare provider right away if you have of liver problems including: I solution. Lopinary ropylene glycol. (stoo sleepy or the contraction of the contraction navir oral soluti ol) and propyler appears too sl Interactions with other medicines. It is important that should not be taken with lopinavir and ritonavi see "Who should not take lopinavir and ritonavir?"
Side Effects in babies taking lopinavir and ritonavir?"
and ritonavir oral solution contains alcohol (ethanol) an your healthcare provider right away if your baby apper breathing changes.
Inflammation of your pancreas (pancreatitis). I can cause pancreatitis which may be serious and may who have high levels of a certain fat (triglycerides) have pancreatitis. If you have advanced HIV-1 disease, you risk of high trinkrearide lavvels in vour blood.

olored a appetite skin and whites of eyes (jaundice) slored urine

Changes in your heart rhythm and the electrical activity of your heart. These changes may be seen on an EKG (electrocardiogram) and can lead to serious heart problems. Your risk for these problems may be higher if you: have a history of abnormal heart rhythm or certain types of heart problems. take other medicines that can affect your heart rhythm during treatment with lopinavir and ritonavir. nsation of abn

REPRODUCTIVE SYSTEM AND BREAST DISORDERS

menstrual disorders - amenorrhea, menorrhagia

lipodystrophy acquired including facial wasting

rash including maculopapular rash*

SKIN AND SUBCUTANEOUS TISSUE DISORDERS

dermatitis/rash including eczema and seborrheic dermatitis

erectile dysfunction*

night sweats'

VASCULAR DISORDERS

pruritus*

alopecia

r antiretroviral in adults and ency Syndrome). other ction i iption medicine that is used with nodeficiency Virus-1 (HIV-1) infe quired Immune Deficie ir is safe and effective See "What a, information about.

See "What is lopinavir and ritonavir is a hedicines to treat Human Imt., children 14 days of age and older. HIV is the virus that causes AIDS (Acquir.) It is not known if lopinavir and ritonavir is sate.

Who should not take lopinavir and ritonavir is sate.

Who should not take lopinavir and ritonavir is sate.

To not take lopinavir and ritonavir is sate.

Who should not take lopinavir ritonavir, or any of the ingrer tablets. See the end of this Medication Guide for a lopinavir and ritonavir tablets.

If you take any of the following medicines:

If you take any of th

edients in lopinavir and ritonavir a complete list of ingredients in

or liver problems.

1.71

 1.7^{2}

3.8

2.2

1.9

1.6

1.1

0.4

0.1

warfarin,

34

10

99

58

50

29

10

the treatment of got containing medicii dihydroergotamine n ergotamine tartrate methylergonovine grazoprevir

(Revatio®), when used for 000000 000

↑ rivaroxaban

your healthcare provider allergic reaction to n perforatum®) you or your child takes te idazolam when taken by mouth idazolam when taken by mouth Lypericum perforoblems can happen if you or ith lopinavir and ritonavir.

B or Hepatitis C. you have a condition Serious problems can happen if you or your dabove with lopinavir and ritonavir.

Before taking lopinavir and ritonavir.

Before taking lopinavir and ritonavir.

• have ever had a serious skin rash or an alle lopinavir or ritonavir.

• have or had pancreas problems.

• have liver problems, including Hepatitis B or have liver problems, including if you Long QT Syndrome.

• have low potassium in your blood.

• have high cholesterol in your blood.

• have hemophilia. Lopinavir and ritonavir mare pregnant or plan to become pregnant.

• will harm your unborn baby.

• Lopinavir and ritonavir oral solution corally because there is no safe level of alcohological.

lopinavir and ritonavir is administered concurrently with vincristine or vinblastine. If the antiretroviral regimen

must be withheld for a prolonged period, consideration

strong CYP3A inhibitors such as lopinavir and ritonavir

Avoid concomitant use of rivaroxaban and lopinavir and

itonavir. Co-administration of lopinavir and ritonavir and

Please refer to the nilotinib and dasatinib prescribing

frequent monitoring of the INR during lopinavir

and ritonavir and warfarin co-administration is

Congenital

called

ormation for dosing instructions.

of

a

about

medicines that

medicines

the

of

A decrease in the dosage or an adjustment of the dosing interval of nilotinib and dasatinib may be necessary for patients requiring co-administration with

igh cholesterol in your blood.

emophilia. Lopinavir and ritonavir may cause increased bleeding.

emophilia. Lopinavir and ritonavir. It is not known if lopinavir and ritor my your unborn baby.

inavir and ritonavir oral solution contains alcohol (ethanol) and propy ol. You should not take lopinavir and ritonavir oral solution during pregnause there is no safe level of alcohol exposure during pregnancy. Tell throare provider if you become pregnant during treatment with Invisitionavir.

Iution contains alcohol (ethanol) and propylene navir and ritonavir oral solution during pregnancy of alcohol exposure during pregnancy. Tell your come pregnant during treatment with lopinavir

parenterally administered

Nasal/Ophthalmic

oetamethasone

dexamethasone

nometasone

budesonide

fluticasone

prednisone

Lopinavir and ritonavir may reduce how well hormonal birth control works. Lopinavir and ritonavir may become pregnant should use another effective form of birth control or an additional barrier method of birth control during treatment with lopinavir and ritonavir.

Pregnancy Registry. There is a pregnancy registry for women who take antiretroviral medicines during pregnancy. The purpose of the pregnancy registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.

not breastfeed if you have HIV-1 ir baby.

provider and pharmacist. or a list of medicines that risk of of the medicines amins, and I Tell your healthcare provider about all the medicines prescription and over-the-counter medicines, vitamins, and Many medicines interact with lopinavir and ritonavir.

Keep a list of your medicines to show your healthcare provider or pharmacist for a interact with lopinavir and ritonavir.

Do not start taking a new medicine without telling your Your healthcare provider can tell you if it is safe to take lopin other medicines. Your healthcare provider may need to che medicines during treatment with lopinavir and ritonavir.

How should I take lopinavir and ritonavir?

Take lopinavir and ritonavir every day exactly as prescrik about the be v-1 to your baby.

k to your healthcare provider abour

r healthcare provider about all

on and over-the-counter medicine
edicines interact with lopinavir an

cour healthcare provider. lopinavir and ritonavir with change the dose of other prescribed by your treatment your

during 1 provider of your healthcare care provider. Stay under the cand ritonavir.

with lopinavir

healthcare

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lopinavir and ritonavir during pregnancy. Physicians are encouraged to register patients by calling the Antiretroviral Pregnancy Registry at 1-800-258-4263 ailable data from the Antiretroviral Pregnancy Registry show no difference in the risk of overall major birth defects compa to the background rate for major birth defects of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) (see Data). The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15 to 20%. The background risk for major birth defects and miscarriage for the indicated population is unknown. Methodological limitations of the APR include the use of MACDP as the external comparator group. The MACDP population is not disease-specific, evaluates women and infants from a limited geographic area, and does not include outcomes for births that occurred at <20 weeks gestation (see Data). No treatment-related malformations were observed when lopinavir in combination with ritonavir was administered to pregnant rats or rabbits; however embryonic and fetal developmental toxicities

Dose Adjustments During Pregnancy and the Postpartum Period

occurred in rats administered maternally toxic doses

Administer 400/100 mg of lopinavir and ritonavir twice daily in pregnant patients with no documented lopinavir-associated resistance substitutions [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)]. There are insufficient data to recommend lopinavir and ritonavir dosing for pregnant patients with any documented lopinavir-associated resistance substitutions. No dose adjustment of lopinavir and ritonavir is required for patients during the postpartum period. Once daily lopinavir and ritonavir dosing is not recommended in pregnancy.

Avoid use of lopinavir and ritonavir oral solution during pregnancy due to the ethanol content. lopinavir and ritonavir oral solution contains the excipients ethanol, approximately 42% (v/v and propylene glycol, approximately 15%.

Lopinavir and ritonavir was evaluated in 12 HIV-infected pregnant women in an open-label pharmacokinetic trial [see Clinical Pharmacology (12.3)]. No new trends in the safety profile were identified in pregnant women dosed with lopinavir and ritonavir compared to the safety described in non-pregnant adults, based on the review of these limited data. Antiretroviral Pregnancy Registry Data: Based on prospective reports from the Antiretroviral Pregnancy Registry (APR) of over 3,000 exposures to lopinavir containing regimens (including over 1,000 exposed in the first trimester), there was no difference between lopinavir and overall birth defects compared with the background birth defect rate of 2.7% in the U.S. reference population of the Metropolitan Atlanta Congenital Defects Program. The prevalence of birth defects in live births was 2.1% (95% CI: 1.4% to 3%) following first-trimester exposure to lopinavir-containing regimens and 3% (95% CI: 2.4% to 3.8%) following second and third trimester exposure to lopinavir-containing regimens. Based on prospective reports from the APR of over 5,000 exposures to ritonavir containing regimens (including over 2,000 exposures in the first trimester) there was no difference between ritonavir and overall birth defects compared with the U.S. background rate (MACDP). The prevalence of birth defects in live births was 2.2% (95% CI: 1.7% to 2.8%) following first-trimester exposure to ritonavir-containing regimens and 2.9% (95% CI: 2.4% to 3.6%) following second and third trimester exposure to ritonavir-containing regimens. For both lopinavir and ritonavir sufficient numbers of first trimester exposures have been monitored to detect at least a 1.5 fold increase in risk of overall birth defects and a 2 fold increase in risk of birth defects in the cardiovascular and genitourinary systems Animal Data

Embryonic and fetal developmental toxicities (early resorption, decreased fetal viability, decreased fetal body weight, increased incidence of skeletal variations and skeletal ossification delays) occurred in rats administered lopinavir in combination with ritonavir (on gestation days 6 to 17) at a maternally toxic dosage. Based on AUC measurements, the drug exposures in rats at the toxic doses were approximately 0.7 times (for lopinavir) and 1.8 times (for ritonavir) the exposures in humans at the recommended therapeutic dose (400/100 mg twice daily). In a pre- and post-natal study in rats, a developmental toxicity (a No embryonic and fetal developmental toxicities were observed in rabbits administered lopinavir in combination with ritonavir (on

decrease in survival in pups between birth and postnatal Day 21) occurred. gestation days 6 to 18) at a maternally toxic dosage. Based on AUC measurements, the drug exposures in rabbits at the toxic doses were approximately 0.6 times (for lopinavir) and similar to (for ritonavir) the exposures in humans at the recommended therapeutic dose (400/100 mg twice daily).

8.2 Lactation Risk Summary
The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV-1. Because of the potential for: 1) HIV transmission (in HIV-negative infants), 2) developing viral resistance (in HIV-positive infants), and 3) adverse reactions in the breastfed infant, instruct mothers not to breastfeed if they are receiving lopinavir and ritonavir. 8.3 Females and Males of Reproductive Potential

<u>Contraception</u> Use of lopinavir and ritonavir may reduce the efficacy of combined hormonal contraceptives. Advise patients using combined hormonal contraceptives to use an effective alternative contraceptive method or an additional barrier method of contraception [see Drug Interactions (7.3)]. 8.4 Pediatric Use

The safety, efficacy, and pharmacokinetic profiles of lopinavir and ritonavir in pediatric patients below the age of 14 days have not been established. Lopinavir and ritonavir should not be administered once daily in pediatric patients. An open-label, multi-center, dose-finding trial was performed to evaluate the pharmacokinetic profile, tolerability, safety and efficacy of lopinavir and ritonavir oral solution containing lopinavir 80 mg/mL and ritonavir 20 mg/mL at a dose of 300/75 mg/m² twice daily plus two NRTIs in HIV-infected infants ≥14 days and < 6 months of age. Results revealed that infants younger than 6 months of age generally had lower lopinavir AUC,, than older children (6 months to 12 years of age), however, despite the lower holinis of age generally near lower logical results of the state of the state of age, individual control of the proportion of subjects who achiev HIV-1 RNA <400 copies/mL at Week 24 [see Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.4)]. Safety and efficacy in pediatric patients > 6 months of age was demonstrated in a clinical trial in 100 patients. The clinical trial was an open-label, multicenter trial evaluating the pharmacokinetic profile, tolerability, safety, and efficacy of lopinavir and was an open-rane, municement that evaluating the pharmacontrible production, tolerability, sately, and enlicacy of opiniavir and ritonavir and marked and experienced pediatric patients ages 6 months to 12 years. Dose selection for patients 6 months to 12 years of age was based on the following results. The 230/57.5 mg/m² oral solution twice daily regimen without nevirapine and the 300/75 mg/m² oral solution twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen (without nevirapine) [see Adverse Reactions (6.2), Clinical Pharmacology (12.3), Clinical Studies (14.4)]. A prospective multicenter, open-label trial evaluated the pharmacokinetic profile, tolerability, safety and efficacy of high-dose Approximation of the pharmacolinary and interval o prior therapy. Patients also had saquinavir mesylate added to their regimen. This strategy was intended to assess whether higher than approved doses of lopinavir and ritonavir could overcome protease inhibitor cross-resistance. High doses of lopinavir and ritonavir exhibited a safety profile similar to those observed in previous trials; changes in HIV-1 RNA were less than anticipated; three patients had HIV-1 RNA <400 copies/mL at Week 48. CD4+ cell count increases were noted in the eight patients who

mained on treatment for 48 weeks [see Adverse Reactions (6.2), Clinical Pharmacology (12.3)]. A prospective multicenter, randomized, open-label study evaluated the efficacy and safety of twice-daily versus once-daily dosing of lopinavir and ritonavir tablets dosed by weight as part of combination antiretroviral therapy (cART) in virologically suppressed HIV-1 infected children (n=173). Children were eligible when they were aged < 18 years, ≥ 15 kg in weight, receiving cART that included lopinavir and ritonavir, HIV-1 ribonucleic acid (RNA) < 50 copies/mL for at least 24 weeks and able to swallow tablets. At week 24, efficacy (defined as the proportion of subjects with plasma HIV-1 RNA less than 50 copies per mL) was significantly higher in subjects receiving twice daily dosing compared to subjects receiving once daily dosing. The safety profile was similar between the two treatment arms although there was a greater incidence of diarrhea in the once daily treated subjects 8.5 Geriatric Use

Clinical studies of lopinavir and ritonavir did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, appropriate caution should be exercised in the administration and monitoring of lopinavir and ritonavir in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac 8.6 Hepatic Impairment

Lopinavir and ritonavir is principally metabolized by the liver; therefore, caution should be exercised when administering this drug to patients with hepatic impairment and Clinical Pharmacology (12.3)]. nent, because lopinavir concentrations may be increased [see Warnings and Precautions (5.4) 10 OVERDOSAGE

Overdoses with lopinavir and ritonavir oral solution have been reported. One of these reports described fatal cardiogenic shock in a 2.1 kg infant who received a single dose of 6.5 mL of lopinavir and ritonavir oral solution (520 mg lopinavir, approximately 10-fold above the recommended lopinavir dose) nine days prior. The following events have been reported in association with unintended overdoses in preterm neonates: complete AV block, cardiomyopathy, lactic acidosis, and acute renal failure [see Warnings and Precautions (5.2)]. Healthcare professionals should be aware that lopinavir and ritonavir oral solution is highly concentrated and therefore, should pay special attention to accurate calculation of the dose of lopinavir and ritonavir, transcription of the medication order, dispensing information and dosing instructions to minimize the risk for medication errors and overdose. This is especially important for infants and young children. Lopinavir and ritonavir oral solution contains approximately 42% (v/v) ethanol and approximately 15% (w/v) propylene glycol

Ingestion of the product over the recommended dose by an infant or a young child could result in significant toxicity and could Human experience of acute overdosage with lopinavir and ritonavir is limited. Treatment of overdose with lopinavir and ritonavir should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with lopinavir and ritonavir. If indicated, elimination of unabsorbed drug should be achieved by gastric lavage. Administration of activated charcoal may also be used to aid in removal of unabsorbed drug. Since lopinavir is highly protein bound, dialysis is unlikely to be beneficial in significant removal of the drug. However, dialysis car

remove both ethanol and propylene glycol in the case of overdose with lopinavir and ritonavir oral solutio 11 DESCRIPTION Lopinavir and ritonavir tablets. USP are a co-formulation of lopinavir USP and ritonavir USP. Lopinavir is an inhibitor of the HIV-1 protease. As co-formulated in lopinavir and ritonavir tablets, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir thereby providing increased plasma levels of lopinavir.

Lopinavir USP is chemically designated as [1S-[1B*,(B*),3B*,4B*]]-N-[4-[[(2,6-dimethylphenoxy)acetyllamino]-3-hydroxy 5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide. Its molecular formula is $C_{37}H_{48}N_4O_5$, and its molecular weight is 628.8 g/mol. Lopinavir USP is a white to off-white color solid. It is freely soluble in ianol, soluble in isopropyl alcohol and practically insoluble in water. Lopinavir USP has the following structural formula:

Ritonavir USP is chemically designated as 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-di-oxo-8,11-bis(phenylmethyl)-5-thiazolylmethylester[5S-(5R*,8R*,10R*,11R*)]-. Its molecular molec formula is $C_3H_{q_0}N_0S_3$, and its molecular weight is 720.94 g/mol. Ritonavir USP is a white or almost white solid. It is freely soluble in methanol and in dichloromethane; very slightly soluble in acetonitrile; practically insoluble in water. Ritonavir USP has the following structural formula:

Lopinavir and ritonavir tablets. USP are available for oral administration in two strengths:

• Yellow tablets containing 200 mg of lopinavir USP and 50 mg of ritonavir USP. Yellow tablets containing 100 mg of lopinavir USP and 25 mg of ritonavir USF The yellow, Lopinavir and Ritonavir Tablets USP, 200 mg/50 mg contain the following inactive ingredients: colloidal silicon

dioxide, copovidone, sodium stearyl fumarate and sorbitan monolaurate. The following are the ingredients in the film coating: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, iron oxide yellow, polyethylene glycol 400, polyethylene glycol 3350, polysorbate 80, talc, and titanium dioxide.

The yellow, Lopinavir and Ritonavir Tablets USP, 100 mg/25 mg contain the following inactive ingredients: colloidal silicon dioxide, copovidone, sodium stearyl fumarate and sorbitan monolaurate. The following are the ingredients in the film coating: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, iron oxide yellow, polyethylene glycol 400, polyethylene glycol 3350, polysorbate 80, talc, and titanium dioxide. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action

Lopinavir and ritonavir is a fixed-dose combination of HIV-1 antiviral drugs lopinavir [see Microbiology (12.4)] and ritonavir. As co-formulated in lopinavir and ritonavir, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir. 12.2 Pharmacodynamics

The effect of lopinavir and ritonavir on QTcF interval was evaluated in a placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 39 healthy adults. The maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline-correction were 5.3 (8.1) and 15.2 (18.0) mseconds (msec) for 400/100 mg twice daily and supratherapeutic 800/200 mg twice daily lopinavir and ritonavir, respectively. Lopinavir and ritonavir 800/200 mg twice daily resulted in a Day 3 mean C approximately 2-fold higher than the mean C observed with the approved once daily and twice daily lopinavir and ritonavir doses at steady state. The maximum mean (95% upper confidence bound) difference from placebo in the PR interval after baseline-correction were 24.9 (21.5, 28.3) and 31.9 (28.5, 35.3) msec for 400/100 mg twice daily and supratherapeutic 800/200 mg twice daily lopinavir and ritonavir, respectively [see Warnings and Precautions (5.5, 5.6)]

The pharmacokinetic properties of lopinavir are summarized in Table 13. The steady-state pharmacokinetic parameters of lopinavir are summarized in Table 14. Under fed conditions, lopinavir concentrations were similar following administration of lopinavir and ritonavir tablets to capsules with less pharmacokinetic variability. Under fed conditions (500 kcal, 25% from fat),

Absorption			
T _{max} (hr) ^a		4.4 ± 0.8	
Effect of meal (relative to fasting) Tablet Oral solution		↑ 19% ^b ↑ 130% ^b	
Distribution			
% Bound to human plasma proteins		> 98	
V _d /Fa (L)		16.9	
Metabolism			
Metabolism		CYP3A	
Elimination			
Major route of elimination		hepatic	
t _{1/2} (h) ^a		6.9 ± 2.2	
% of dose excreted in urine		10.4 ± 2.3	
% of dose excreted in feces		82.6 ± 2.5	
a. Lopinavir and ritonavir tablet b. Changes in AUC values			
able 14. Steady-State Pharmacokinetic Parameters of Lopinavii	, Mean ± SD		
Dharmanakinatic Barameter	Twice Dailys	Once Daily	

a. Lopinavir and ritonavir tablet b. Changes in AUC values		
Table 14. Steady-State Pharmacokinetic Parameters of Lopina	rir, Mean ± SD	
Pharmacokinetic Parameter	Twice Daily ^a	Once Daily ^b
C _{max} (mcg/mL)	9.8 ± 3.7	11.8 ± 3.7
C _{min} (mcg/mL)	5.5 ± 2.7	1.7 ± 1.6
AUC _{tau} (mcg•h/mL)	92.6 ± 36.7	154.1 ± 61.4
a. 19 HIV-1 subjects, lopinavir and ritonavir 400/100 mg twice dai		00 mg

Specific Populations

No gender or race related pharmacokinetic differences have been observed in adult patients. Lopinavir pharmacokinetics have not been studied in elderly patients.

The 230/57.5 mg/m² twice daily regimen without nevirapine and the 300/75 mg/m² twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen without

C _{max} (mcg/mL)	C _{min} (mcg/mL)	AUC ₁₂ (mcg·hr/m)
	Age ≥ 14 Days to < 6 Weeks Cohort (N	= 9):
5.17 ± 1.84 ^a	1.40 ± 0.48a	43.39 ± 14.80 ^a
	Age ≥ 6 Weeks to < 6 Months Cohort (N	= 18):
9.39 ± 4.91 ^a	1.95 ± 1.80°	74.50 ± 37.87a
	Age ≥ 6 Months to ≤ 12 years Cohort (N	= 24):
8.2 ± 2.9 ^b	3.4 ± 2.1 ^b	72.6 ± 31.1 ^b
10.0 ± 3.3°	3.6 ± 3.5°	85.8 ± 36.9°
Lopinavir and ritonavir oral se	blution 300/75 mg/m² twice daily without concomi olution 230/57.5 mg/m² twice daily without nevira olution 300/75 mg/m² twice daily with nevirapine (pine (n=12)

Fregnancy
The C_{12n} values of lopinavir were lower during the second and third trimester by approximately 40% as compared to postpartum in 12 HIV-infected pregnant women received lopinavir and ritonavir 400 mg/100 mg twice daily. Yet this decrease is not
considered clinically relevant in patients with no documented lopinavir and ritonavir-associated resistance substitutions receiving Renal Impairment Lopinavir pharmacokinetics have not been studied in patients with renal impairment; however, since the renal clearance of

Multiple dosing of lopinavir and ritonavir 400/100 mg twice daily to HIV-1 and HCV co-infected patients with mild to moderate

hepatic impairment (n = 12) resulted in a 30% increase in lopinavir AUC and 20% increase in C_{max} compared to HIV-1 infected subjects with normal hepatic function (n = 12). Additionally, the plasma protein binding of lopinavir was statistically significantly lower in both mild and moderate hepatic impairment compared to controls (99.09 vs. 99.31%, respectively). Lopinavir and ritonavir has not been studied in patients with severe hepatic impairment [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6)]. Drug Interactions and ritonavir is an inhibitor of the P450 isoform CYP3A in vitro. Lopinavir and ritonavir does not inhibit CYP2D6,

CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations. Lopinavir and ritonavir has been shown in vivo to induce its own metabolism and to increase the biotransformation of some drugs etabolized by cytochrome P450 enzymes and by glucuronidation. The effects of co-administration of lopinavir and ritonavir on the AUC, C_{max} and C_{min} are summarized in Table 16 (effect of

other drugs on lopinavir) and Table 17 (effect of lopinavir and ritonavir on other drugs). For information regarding clinical recommendations, see Table 12 in Drug Interactions (7).

is Generics Inc. at 1-83; rks of their respective cakers of these brands a akers of these brands or its products.

owr

s and are affiliated

not t

do r

U.S.

mg/25 mg: colloidal silicon dioxide, bitan monolaurate. The following are icon dioxide, hydroxypropyl cellulose, glycol 400, polyethylene glycol 3350,

Co- administered Drug	Dose of Co- administered Drug (mg)	Dose of Lopinavir and Ritonavir (mg)	n	Ratio (in combination with Co-administered drug/alone) of Lopinavir Pharmacokinetic Parameters (90% CI); No Effect = 1.00		
				C _{max}	AUC	C _{min}
Efavirenz ¹	600 at bedtime	400/100 capsule twice daily	11, 7³	0.97 (0.78, 1.22)	0.81 (0.64, 1.03)	0.61 (0.38, 0.97)
	600 at bedtime	500/125 tablet twice daily	19	1.12 (1.02, 1.23)	1.06 (0.96, 1.17)	0.90 (0.78, 1.04)
	600 at bedtime	600/150 tablet twice daily	23	1.36 (1.28, 1.44)	1.36 (1.28, 1.44)	1.32 (1.21, 1.44)
Etravirine	200 twice daily	400/100 mg twice daily (tablets)	16	0.89 (0.82 to 0.96)	0.87 (0.83 to 0.92)	0.80 (0.73 to 0.88)
Fosamprenavir ²	700 twice daily plus ritonavir 100 twice daily	400/100 capsule twice daily	18	1.30 (0.85, 1.47)	1.37 (0.80, 1.55)	1.52 (0.72, 1.82)
Ketoconazole	200 single dose	400/100 capsule twice daily	12	0.89 (0.80, 0.99)	0.87 (0.75, 1.00)	0.75 (0.55, 1.00)
Nelfinavir	1,000 twice daily	400/100 capsule twice daily	13	0.79 (0.70, 0.89)	0.73 (0.63, 0.85)	0.62 (0.49, 0.78)
	200 twice daily steady-state	400/100 capsule twice daily	22, 19³	0.81 (0.62, 1.05)	0.73 (0.53, 0.98)	0.49 (0.28, 0.74)
Nevirapine	7 mg/kg or 4 mg/kg once daily; twice daily 1 wk ⁵	(> 1 yr) 300/ 75 mg/m² oral solution twice daily	12, 15³	0.86 (0.64, 1.16)	0.78 (0.56, 1.09)	0.45 (0.25, 0.81)
Ombitasvir/ paritaprevir/ ritonavir+ dasabuvir²	25/150/100 + dasabuvir 400	400/100 tablet twice daily	6	0.87 (0.76, 0.99)	0.94 (0.81, 1.10)	1.15 (0.93, 1.42)
O	40 once daily, 5 d	400/100 tablet twice daily, 10 d	12	1.08 (0.99, 1.17)	1.07 (0.99, 1.15)	1.03 (0.90, 1.18)
Omeprazole	40 once daily, 5 d	800/200 tablet once daily, 10 d	12	0.94 (0.88, 1.00)	0.92 (0.86, 0.99)	0.71 (0.57, 0.89)
Pravastatin	20 once daily, 4 d	400/100 capsule twice daily, 14 d	12	0.98 (0.89, 1.08)	0.95 (0.85, 1.05)	0.88 (0.77, 1.02)
	150 single dose	400/100 tablet twice daily, 10 d	12	0.99 (0.95, 1.03)	0.97 (0.93, 1.01)	0.90 (0.85, 0.95)
Ranitidine	150 single dose	800/200 tablet once daily, 10 d	10	0.97 (0.95, 1.00)	0.95 (0.91, 0.99)	0.82 (0.74, 0.91)
Rifabutin	150 once daily	400/100 capsule twice daily	14	1.08 (0.97, 1.19)	1.17 (1.04, 1.31)	1.20 (0.96, 1.65)
Rifampin	600 once daily	400/100 capsule twice daily	22	0.45 (0.40, 0.51)	0.25 (0.21, 0.29)	0.01 (0.01, 0.02)
	600 once daily	800/200 capsule twice daily	10	1.02 (0.85, 1.23)	0.84 (0.64, 1.10)	0.43 (0.19, 0.96)
	600 once daily	400/400 capsule twice daily	9	0.93 (0.81, 1.07)	0.98 (0.81, 1.17)	1.03 (0.68, 1.56)
Rilpivirine	150 once daily	400/100 twice daily (capsules)	15	0.96 (0.88 to 1.05)	0.99 (0.89 to 1.10)	0.89 (0.73 to 1.08)
Ritonavir	100 twice daily	400/100 capsule twice daily	8, 21 ³	1.28 (0.94, 1.76)	1.46 (1.04, 2.06)	2.16 (1.29, 3.62)
Tipranavir/ ritonavir	500/200 twice daily	400/100 capsule twice daily	21, 69³	0.53 (0.40, 0.69)	0.45 (0.32, 0.63)	0.30 (0.17, 0.51) 0.48 ⁴

Table 16. Drug Interactions: Pharmacokinetic Parameters for Lopinavir in the Presence of the Co-administered Drug for

Alterations in Dose or Reg

Reference for comparison is lopinavir/ritonavir 400/100 mg twice daily without efavirenz. Data extracted from the U.S. prescribing information of co-adm Parallel group design Drug levels obtained at 8 to 16 hours post dose

Co- administered Drug	Dose of Co- administered Drug (mg)	Dose of Lopinavir and Ritonavir (mg)	n	Ratio (in combination with Lopinavir and Ritonavir/alone) of Co-administered Drug Pharmacokinetic Parameters (90% CI); No Effect = 1.00			
				C _{max}	AUC	C _{min}	
Bedaquiline ¹	400 single dose	400/100 twice daily	N/A	N/A	1.22 (1.11, 1.34)	N/A	
Efavirenz	600 at bedtime	400/100 capsule twice daily	11, 12³	0.91 (0.72, 1.15)	0.84 (0.62, 1.15)	0.84 (0.58, 1.20)	
Elbasvir/ grazoprevir¹	50 once daily		10	2.87 (2.29, 3.58)	3.71 (3.05, 4.53)	4.58 (3.72, 5.64)	
	200 once daily	400/100 twice daily	13	7.31 (5.65, 9.45)	12.86 (10.25, 16.13)	21.70 (12.99, 36.25)	
Ethinyl Estradiol	35 mcg once daily (Ortho Novum®)	400/100 capsule twice daily	12	0.59 (0.52, 0.66)	0.58 (0.54, 0.62)	0.42 (0.36, 0.49)	
Etravirine	200 twice daily	400/100 tablet twice day	16	0.70 (0.64 to 0.78)	0.65 (0.59 to 0.71)	0.55 (0.49 to 0.62)	
Fosamprenavir ¹	700 twice daily plus ritonavir 100 twice daily	400/100 capsule twice daily	18	0.42 (0.30, 0.58)	0.37 (0.28, 0.49)	0.35 (0.27, 0.46)	
Indinavir	600 twice daily combo nonfasting vs. 800 three times daily alone fasting	400/100 capsule twice daily	13	0.71 (0.63, 0.81)	0.91 (0.75, 1.10)	3.47 (2.60, 4.64)	
Ketoconazole	200 single dose	400/100 capsule twice daily	12	1.13 (0.91, 1.40)	3.04 (2.44, 3.79)	N/A	
Maraviroc ¹	300 twice daily	400/100 twice daily	11	1.97 (1.66, 2.34)	3.95 (3.43, 4.56)	9.24 (7.98, 10.7)	
Methadone	5 single dose	400/100 capsule twice daily	11	0.55 (0.48, 0.64)	0.47 (0.42, 0.53)	N/A	
Nelfinavir	1,000 twice daily combo vs. 1,250 twice daily alone	400/100 capsule twice daily	13	0.93 (0.82, 1.05)	1.07 (0.95, 1.19)	1.86 (1.57, 2.22)	
M8 metabolite				2.36 (1.91, 2.91)	3.46 (2.78, 4.31)	7.49 (5.85, 9.58)	
Nevirapine	200 once daily twice daily	400/100 capsule twice daily	5, 6 ³	1.05 (0.72, 1.52)	1.08 (0.72, 1.64)	1.15 (0.71, 1.86)	
Norethindrone	1 once daily (Ortho Novum®)	400/100 capsule twice daily	12	0.84 (0.75, 0.94)	0.83 (0.73, 0.94)	0.68 (0.54, 0.85)	
Ombitasvir/		400/100		1.14 (1.01, 1.28) 2.04	1.17 (1.07, 1.28) 2.17	1.24 (1.14, 1.34) 2.36	
paritaprevir/ ritonavir+ dasabuvir¹	25/150/100 + dasabuvir 400	tablet twice daily	6	(1.30, 3.20) 1.55 (1.16, 2.09) 0.99	(1.63, 2.89) 2.05 (1.49, 2.81) 0.93	(1.00, 5.55) 5.25 (3.33, 8.28) 0.68	
		400/100 tablet		(0.75, 1.31) 0.96	(0.75, 1.15) 0.80	(0.57, 0.80)	
Pitavastatin ¹	4 once daily	twice daily	23	(0.84 to 1.10)	(0.73 to 0.87)	N/A	
Pravastatin	20 once daily	400/100 capsule twice daily	12	1.26 (0.87, 1.83)	1.33 (0.91, 1.94)	N/A	
Rifabutin	150 once daily combo vs. 300 once daily alone	400/100 capsule twice daily	12	2.12 (1.89, 2.38)	3.03 (2.79, 3.30)	4.90 (3.18, 5.76)	
25- <i>O</i> -desacetyl rifabutin				23.6 (13.7, 25.3)	47.5 (29.3, 51.8)	94.9 (74.0, 122)	
Rifabutin + 25- <i>O</i> -desacetyl rifabutin				3.46 (3.07, 3.91)	5.73 (5.08, 6.46)	9.53 (7.56, 12.01)	
Rilpivirine	150 once daily	400/100 capsules twice daily	15	1.29 (1.18 to 1.40)	1.52 (1.36 to 1.70)	1.74 (1.46 to 2.08)	
Rosuvastatin²	20 once daily	400/100 tablet twice daily	15	4.66 (3.4, 6.4)	2.08 (1.66, 2.6)	1.04 (0.9, 1.2)	
Tenofovir alafenamide¹	10 once daily	800/200 tablet once daily	10	2.19 (1.72, 2.79)	1.47 (1.17, 1.85)	N/A	
Tenofovir disoproxil fumarate ¹	300 once daily	400/100 capsule twice daily	24	No Change	1.32 (1.26, 1.38)	1.51 (1.32, 1.66)	

twice daily Data extracted from the U.S. prescribing information of co-administered drugs. Kiser, et al. J Acquir Immune Defic Syndr. 2008 Apr 15: 47(5):570-8.

N/A = Not available.12.4 Microbiology

Mechanism of Action
Lopinavir, an inhibitor of the HIV-1 protease, prevents cleavage of the viral Gag-Pol polyprotein, resulting in the production of immature, non-infectious viral particles. **Antiviral Activity**

In the absence of human serum, the mean 50% effective concentration (EC₅₀) values of lopinavir against five different HIV-1 subtype B laboratory strains in lymphoblastic cell lines ranged from 10 to 27 nM (0.006 to 0.017 mcg/mL, 1 mcg/mL = 1.6 mcM), and ranged from 4 to 11 nM (0.003 to 0.007 mcg/mL) against several HIV-1 subtype B clinical isolates in peripheral blood lymphocytes (n = 6). In the presence of 50% human serum, the mean EC_{50} values of lopinavir against these five HIV-1 laboratory strains ranged from 65 to 289 nM (0.04 to 0.18 mcg/mL), representing a 7 to 11-fold attenuation. The EC_{50} values of lopinavir against three different HIV-2 strains ranged from 12 to 180 nM (0.008 to 113 mcg/mL). Resistance HIV-1 isolates with reduced susceptibility to lopinavir have been selected in cell culture. The presence of ritonavir does not appear to influence the selection of lopinavir-resistant viruses in cell culture.

In a study of 653 antiretroviral treatment-naïve patients (Study 863), plasma viral isolates from each patient on treatment with plasma HIV-1 RNA >400 copies/mL at Week 24, 32, 40 and/or 48 were analyzed. No specific amino acid substitutions could be associated with resistance to lopinavir and ritonavir in the virus from 37 evaluable lopinavir and ritonavir-treated patients. The selection of resistance to lopinavir and ritonavir in antiretroviral treatment-naïve pediatric patients (Study 940) appears to be consistent with that seen in adult patients (Study 863). Resistance to lopinavir and ritonavir has been noted to emerge in patients treated with other protease inhibitors prior to lopinavir

and ritonavir therapy. In studies of 227 antiretroviral treatment-naive and protease inhibitor experienced patients, isolates from 4 of 23 patients with quantifiable (>400 copies/mL) viral RNA following treatment with lopinavir and ritonavir for 12 to 100 weeks displayed significantly reduced susceptibility to lopinavir compared to the corresponding baseline viral isolates. All four of these patients had previously received treatment with at least one protease inhibitor and had at least 4 substitutions associated with protease inhibitor resistance immediately prior to lopinavir and ritonavir therapy. Following viral rebound, isolates from these patients all contained additional substitutions, some of which are recognized to be associated with protease inhibitor resistance.

<u>Cross-resistance - Nonclinical Studies</u>
Varying degrees of cross-resistance have been observed among HIV-1 protease inhibitors. The antiviral activity in cell culture of lopinavir against clinical isolates from patients previously treated with a single protease inhibitor was determined (Table 18). Table 18.

Susceptibility reduced by >4 fold	Susceptibility reduced to LPV
Indinavir (n=16)	5.7 fold
Nelfinavir (n=13)	<4 fold
Ritonavir (n=3)	8.32 fold
Saquinavir (n=4)	<4 fold

Clinical Studies - Antiviral Activity of Lopinavir and Ritonavir in Patients with Previous Protease Inhibitor Therapies to lopinavir and ritonavir therapy in treatment-experienced patients, with respect to baseline viral genotype in three studies and baseline viral phenotype in one study.

Virologic response to lopinavir and ritonavir has been shown to be affected by the presence of three or more of the following amino acid substitutions in protease at baseline: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. Table 19 shows the 48-week virologic response (HIV-1 RNA <400 copies/mL) according to the number of the above protease inhibitor resistance-associated substitutions at baseline in studies 888 and 765 [see Clinical Studies (14.2) and (14.3)] and study 957 (see below). Once daily administration of lopinavir and ritonavir for adult patients with three or more of the above substitutions is not recommended.

Number of protease	Study 888 (Single protease inhibitor-experienced², NNRTI-naïve) n=130	Study 765 (Single protease	Study 957 (Multiple protease inhibitor-experienced ⁴ , NNRTI-naïve) n=50				
0 to 2	76/103 (74%)	34/45 (76%)	19/20 (95%)				
3 to 5	13/26 (50%)	8/11 (73%)	18/26 (69%)				
6 or more 0/1 (0%) N/A 1/4 (25%)							
F/S/T, and I84V.	Substitutions considered in the analysis included L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/						

41% indinavir, 38% nelfinavir, 4% ritonavir, 16% saquinavir.
86% indinavir, 54% nelfinavir, 80% ritonavir, 70% saquinavir. Virologic response to lopinavir and ritonavir therapy with respect to phenotypic susceptibility to lopinavir at baseline was examined in Study 957. In this study 56 NNRTI-naïve patients with HIV-1 RNA >1,000 copies/mL despite previous therapy with at least two protease inhibitors selected from indinavir, nelfinavir, ritonavir, and saquinavir were randomized to receive one of two doses of lopinavir and ritonavir in combination with efavirenz and nucleoside reverse transcriptase inhibitors (NRTIs). The EC_{so} values of lopinavir against the 56 baseline viral isolates ranged from 0.5- to 96-fold the wild-type EC 👝 value. Fifty-five percent (31/56) of these baseline isolates displayed >4-fold reduced susceptibility to lopinavir. These 31 isolates had a median reduction in lopinavir susceptibility of 18-fold. Response to therapy by baseline lopinavir susceptibility is shown in Table 20.

Table 20. HIV-1 RNA Response at Week 48 by Baseline Lopinavir Susceptibility¹

Lopinavii susceptibility at baseline	Tilv-1 HNA C400 Copies/IIIL (76)	Tilv-1 Hiva C30 copies/iiic (70)
< 10 fold	25/27 (93%)	22/27 (81%)
> 10 and < 40 fold	11/15 (73%)	9/15 (60%)
≥ 40 fold	2/8 (25%)	2/8 (25%)
 Lopinavir susceptibility was determined by Fold change in susceptibility from wild type 		ormed by Virologic.
13 NONCLINICAL TOXICOLOGY		

Carcinogenesis

lopinavir, as described in the following section.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Lopinavir/ritonavir combination was evaluated for carcinogenic potential by oral gavage administration to mice and rats for up to 104 weeks. Results showed an increase in the incidence of benign hepatocellular adenomas and an increase in the combined incidence of hepatocellular adenomas plus carcinoma in both males and females in mice and males in rats at doses that produced approximately 1.6 to 2.2 times (mice) and 0.5 times (rats) the human exposure (based on AUC_0 to 244v measurement at the recommended dose of 400/100 mg lopinavir and ritonavir twice daily. Administration of lopinavir/ritonavir did not cause a statistically significant increase in the incidence of any other benign or malignant neoplasm in mice or rats. Carcinogenicity studies in mice and rats have been carried out on ritonavir. In male mice, there was a dose dependent increase exposure at the high dose was approximately 4-fold for males that of the exposure in humans with the recommended therapeutic dose (400/100 mg lopinavir and ritonavir twice daily). There were no carcinogenic effects seen in females at the dosages ested. The exposure at the high dose was approximately 9-fold for the females that of the exposure in humans. There were no carcinogenic effects in rats. In this study, the exposure at the high dose was approximately 0.7-fold that of the exposure in

Neither lopinavir nor ritonavir was found to be mutagenic or clastogenic in a battery of in vitro and in vivo assays including the Ames bacterial reverse mutation assay using *S. typhimurium* and *E. coli*, the mouse lymphoma assay, the mouse micron test and chromosomal aberration assays in human lymphocytes.

humans with the 400/100 mg lopinavir and ritonavir twice daily regimen. Based on the exposures achieved in the animal studies,

Lopinavir in combination with ritonavir at a 2:1 ratio produced no effects on fertility in male and remaie rats at revers or 10/3, 00/10 or 100/50 mg/kg/day. Based on AUC measurements, the exposures in rats at the high doses were approximately 0.7-fold for 14 CLINICAL STUDIES 14.1 Adult Patients without Prior Antiretroviral Therapy

Study 863: Lopinavir and Ritonavir Capsules twice daily + stavudine + lamivudine compared to nelfinavir three times daily + Study 863 was a randomized, double-blind, multicenter trial comparing treatment with lopinavir and ritonavir capsules (400/100 mg twice daily) plus stavudine and lamivudine versus nelfinavir (750 mg three times daily) plus stavudine and lamivudine in 653 antiretroviral treatment naïve patients. Patients had a mean age of 38 years (range: 19 to 84), 57% were Caucasian, and 80% were male. Mean baseline CD4+ cell count was 259 cells/mm³ (range: 2 to 949 cells/mm³) and mean baseline plasma HIV-1 RNA was 4.9 log₁₀ copies/mL (range: 2.6 to 6.8 log₁₀ copies/mL). Treatment response and outcomes of randomized treatment are presented in Table 21

discontinuation through Week 48, lopinavir and ritonavir arm and 24	including patients v	who discontinued si				the
nrough 48 weeks of therapy, there wompared to the nelfinavir arm with h7% vs. 52%, respectively). Treatme	HIV-1 RNA < 400 co	opies/mL (75% vs.	62%,	respectively) and H	IIV-1 RNA < 50 c	
ble 22. Proportion of Responders	s Through Week 4	8 by Baseline Vira	Load	d (Study 863)		
Baseline Viral Load (HIV- 1 RNA copies/mL)	Lopinavir and Ritonavir+d4T+3TC		С	Nelfina	vir +d4T+3TC	
	<400 copies/mL ¹	<50 copies/mL ²	n	<400 copies/mL ¹	<50 copies/mL ²	n
30,000	749/	710/	00	709/	700/	07

Lopinavir and

(N = 326)

75%

9% 7%

2%

10%

Table 21. Outcomes of Randomized Treatment Through Week 48 (Study 863)

Patients achieved and maintained confirmed HIV-1 RNA < 400 copies/mL through Week Includes confirmed viral rebound and failure to achieve confirmed < 400 copies/mLthrough Week 48.

Outcome

Never suppressed through Week 48

Discontinued due to adverse events

Discontinued for other reasons³

Responder¹

Virologic failure

Rebound

Baseline Viral Load (HIV- 1 RNA copies/mL)	Lopinavir and Ritonavir+d4T+3TC		Nelfinavir +d4T+3TC			
	<400 copies/mL ¹	<50 copies/mL ²	n	<400 copies/mL ¹	<50 copies/mL ²	n
30,000	74%	71%	82	79%	72%	87
30,000 to < 100,000	81%	73%	79	67%	54%	79
100,000 to < 250,000	75%	64%	83	60%	47%	72
250,000	72%	60%	82	44%	33%	89
Patients achieved and maintained Patients achieved HIV-1 RNA < 50			nL thro	ugh Week 48.		

Study 730: Lopinavir and Ritonavir Tablets once daily + tenofovir DF + emtricitabine compared to Lopinavir and Ritonavir Tablets wice daily + tenofovir DF + emtricitabine
Study 730 was a randomized, open-label, multicenter trial comparing treatment with lopinavir and ritonavir 800/200 mg once daily plus tenofovir DF and emtricitabine versus lopinavir and ritonavir 400/100 mg twice daily plus tenofovir DF and emtri in 664 antiretroviral treatment-naïve patients. Patients were randomized in a 1:1 ratio to receive either lopinavir and ritonavir 800/200 mg once daily (n = 333) or lopinavir and ritonavir 400/100 mg twice daily (n = 331). Further stratification within each group was 1:1 (tablet vs. capsule). Patients administered the capsule were switched to the tablet formulation at Week 8 and maintained on their randomized dosing schedule. Patients were administered met switched to the latest infinited and the maintained on their randomized dosing schedule. Patients were administered emricitabine 200 mg once daily and tenofovir DF 300 mg once daily. Mean age of patients enrolled was 39 years (range: 19 to 71); 75% were Caucasian, and 78% were male. Mean baseline CD4+ cell count was 216 cells/mm³ (range: 20 to 775 cells/mm³) and mean baseline plasma HIV-1 RNA was 5.0

log₁₀ copies/mL (range: 1.7 to 7.0 log₁₀ copies/mL). Treatment response and outcomes of randomized treatment through Week 48 are presented in Table 23.

Outcome	Lopinavir and Ritonavir Once Daily + TDF + FTC (n = 333)	Lopinavir and Ritonavir Twice Daily + TDF + FTC (n = 331)
Responder ¹	78%	77%
Virologic failure ² Rebound Never suppressed through Week 48	10% 5% 5%	8% 5% 3%
Death	1%	<1%
Discontinued due to adverse events	4%	3%
Discontinued for other reasons ³	8%	11%
Patients achieved and maintained confirmed HIV-1 RI Includes confirmed viral rebound and failure to achiev Includes lost to follow-up, patient's withdrawal, non-co	re confirmed < 50 copies/mL throug	h Week 48.

Through 48 weeks of therapy, 78% in the lopinavir and ritonavir once daily arm and 77% in the lopinavir and ritonavir twice daily arm achieved and maintained HIV-1 RNA < 50 copies/mL (95% confidence interval for the difference, -5.9% to 6.8%). Mean CD4+ cell count increases at Week 48 were 186 cells/mm³ for the lopinavir and rittonavir once daily arm and 198 cells/mm³ for the lopinavir and ritonavir twice daily arm.

14.2 Adult Patients with Prior Antiretroviral Therapy Study 888: Lopinavir and Ritonavir Capsules twice daily + nevirapine + NRTIs compared to investigator-selected protease nhibitor(s) + nevirapine + NRTIs Study 888 was a randomized, open-label, multicenter trial comparing treatment with lopinavir and ritonavir capsules (400/100 mg twice daily) plus nevirapine and nucleoside reverse transcriptase inhibitors versus investigator-selected protease inhibitor(s) plus nevirapine and nucleoside reverse transcriptase inhibitors in 288 single protease inhibitor-experienced, non-nucleoside reverse transcriptase inhibitor (NNRTI)-naïve patients. Patients had a mean age of 40 years (range: 18 to 74), 68% were Caucasian, and 86% were male. Mean baseline CD4+ cell count was 322 cells/mm³ (range: 10 to 1,059 cells/mm³) and mean baseline plasma HIV-1 RNA was 4.1 log, copies/mL (range: 2.6 to 6.0 log, copies/mL). Treatment response and outcomes of randomized treatment through Week 48 are presented in Table 24.

Outcome	Lopinavir and Ritonavir + nevirapine + NRTIs (n = 148)	Investigator-Selected Protease Inhibitor(s) + nevirapine + NRTIs (n = 140)
Responder ¹	57%	33%
Virologic failure ² Rebound Never suppressed through Week 48	24% 11% 13%	41% 19% 23%
Death	1%	2%
Discontinued due to adverse events	5%	11%
Discontinued for other reasons ³	14%	13%
Discontinued for other reasons ³ 1 Patients achieved and maintained confirmed 2 Includes confirmed viral rebound and failure t	HIV-1 RNA < 400 copies/mL through Wee o achieve confirmed < 400 copies/mL thro	ek 48. bugh Week 48.

Inrough 48 weeks of therapy, there was a statistically significantly higher proportion of patients in the lopinavir and ritohavir arr compared to the investigator-selected protease inhibitor(s) arm with HIV-1 RNA < 400 copies/mL (57% vs. 33%, respectively). Through 48 weeks of therapy, the mean increase from baseline in CD4+ cell count was 111 cells/mm3 for the lopinavir and ritonavir arm and 112 cells/mm3 for the investigator-selected protease inhibitor(s) arm. Study 802: Lopinavir and Ritonavir Tablets 800/200 mg Once Daily Versus 400/100 mg Twice Daily when Co-administered with

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced, HIV-1 Infected Subjects
M06-802 was a randomized open-label study comparing the safety, tolerability, and antiviral activity of once daily and twice daily
dosing of lopinavir and ritonavir tablets in 599 subjects with detectable viral loads while receiving their current antiviral therapy. Of the enrolled subjects, 55% on both treatment arms had not been previously treated with a protease inhibitor and 81 to 88% Of the efficiency subjects, 53% of both realment after his his of been previously fleated with a professer limitor and a fit of 10 85% had received prior NNRTIs as part of their anti-HIV treatment regimen. Patients were randomized in a 1:1 ratio to receive either lopinavir and ritonavir 800/200 mg once daily (n = 300) or lopinavir and ritonavir 400/100 mg twice daily (n = 299). Patients were administered at least two nucleoside/nucleotide reverse transcriptase inhibitors selected by the investigator. Mean age of patients enrolled was 41 years (range: 21 to 73); 51% were Caucasian, and 66% were male. Mean baseline CD4+ cell count was 254 cells/mm³ (range: 4 to 952 cells/mm³) and mean baseline plasma HIV-1 RNA was 4.3 log₁₀ copies/mL (range: 1.7 to 6.6 log₁₀ copies/mL). Treatment response and outcomes of randomized treatment through Week 48 are presented in Table 25.

Outcome	Lopinavir and Ritonavir Once Daily + NRTIs (n = 300)	Lopinavir and Ritonavir Twice Daily + NRTIs (n = 299)
irologic Success (HIV-1 RNA <50 copies/mL)	57%	54%
irologic failure¹	22%	24%
o virologic data in Week 48 window		
iscontinued study due to adverse vent or death²	5%	7%
iscontinued study for other reasons ³	13%	12%
lissing data during window but on study	3%	3%
Includes patients who discontinued prior to Weel mL at Week 48. Includes patients who discontinued due to adver in no virologic data on treatment at Week 48. Includes withdrawal of consent, loss to follow-up.	se events or death at any time from D	oay 1 through Week 48 if this result

Through 48 weeks of treatment, the mean change from baseline for CD4+ cell count was 135 cells/mm3 for the once daily group and 122 cells/mm3 for the twice daily group 14.3 Other Studies Supporting Approval in Adult Patients

Study 720: Lopinavir and ritonavir twice daily + stavudine + lamivudine Study 765: Lopinavir and ritonavir twice daily + nevirapine + NRTIs

Study 720 (patients without prior antiretroviral therapy) and study 765 (patients with prior protease inhibitor therapy) were randomized, blinded, multi-center trials evaluating treatment with lopinavir and ritonavir at up to three dose levels (200/100 mg twice daily [720 only], 400/100 mg twice daily, and 400/200 mg twice daily). In Study 720, all patients switched to 400/100 mg wice daily between Weeks 48 to 72. Patients in study 720 had a mean age of 35 years, 70% were Caucasian, and 96% were nale, while patients in study 765 had a mean age of 35 years, 70% were male. Mean (range) baseline CD4+ cell counts for patients in study 720 and study 765 were 338 (3 to 918) and 372 (72 to 807) cells/mm³, resp range) baseline plasma HIV-1 RNA levels for patients in study 720 and study 765 were 4.9 (3.3 to 6.3) and 4.0 (2.9 to 5.8) \log_{10} copies/mL, respectively. Through 360 weeks of treatment in study 720, the proportion of patients with HIV-1 RNA < 400 (< 50) copies/mL was 61% (59%)

[n = 100]. Among patients completing 360 weeks of treatment with CD4+ cell count measurements [n=60], the mean (median) increase in CD4+ cell count was 501 (457) cells/mm³. Thirty-nine patients (39%) discontinued the study, including 13 (13%) discontinuations due to adverse reactions and 1 (1%) death. Through 144 weeks of treatment in study 765, the proportion of patients with HIV-1 RNA < 400 (< 50) copies/mL was 54% (50%) [in = 70], and the corresponding mean increase in CD4+ cell count was 212 cells/mm³. Twenty-seven patients (39%) discontinued the study, including 5 (7%) discontinuations secondary to adverse reactions and 2 (3%) deaths. 14.4 Pediatric Studies

Study 1030 was an open-label, multicenter, dose-finding trial evaluating the pharmacokinetic profile, tolerability, safety and efficacy of lopinavir and ritonavir oral solution containing lopinavir 80 mg/mL and ritonavir 20 mg/mL at a dose of 300/75 mg/m² twice daily plus 2 NRTIs in HIV-1 infected infants ≥14 days and <6 months of age. Ten infants, ≥14 days and <6 wks of age, were enrolled at a median (range) age of 5.7 (3.6 to 6.0) weeks and all completed 24 weeks. At entry, median (range) HIV-1 RNA was 6.0 (4.7 to 7.2) log₁₀ copies/mL. Seven of 10 infants had HIV-1 RNA <400 copies/

mL at Week 24. At entry, median (range) CD4+ percentage was 41 (16 to 59) with a median decrease of 1% (95% CI: -10, 18) from baseline to week 24 in 6 infants with available data. Twenty-one infants, between 6 weeks and 6 months of age, were enrolled at a median (range) age of 14.7 (6.9 to 25.7) weeks and 19 of 21 infants completed 24 weeks. At entry, median (range) HIV RNA level was 5.8 (3.7 to 6.9) \log_{10} copies/mL. Ten of 21 infants had HIV RNA <400 copies/mL at Week 24. At entry, the median (range) CD4+ percentage was 32 (11 to 54) with a median increase of 4% (95% CI: -1, 9) from baseline to week 24 in 19 infants with available data [see Clinical Pharmacology

(12.3) for pharmacokinetic results]. Study 940 was an open-label, multicenter trial evaluating the pharmacokinetic profile, tolerability, safety and efficacy of lopinavir and ritonavir oral solution containing lopinavir 80 mg/mL and ritonavir 20 mg/mL in 100 antiretroviral naïve (44%) and experienced (56%) pediatric patients. All patients were non-nucleoside reverse transcriptase inhibitor naïve. Patients were randomized to (30%) pediatric patients. An patients were non-induced to every a transcriptase limitor have. Patients were randomized to either 230 mg lopinavir/57.5 mg ritonavir per m² or 300 mg lopinavir/75 mg ritonavir per m² or 300 mg lopinavir/75 mg ritonavir per m². Naïve patients also received lamivudine and stavudine. Experienced patients received nevirapine plus up to two nucleoside reverse transcriptase inhibitors. Safety, efficacy and pharmacokinetic profiles of the two dose regimens were assessed after three weeks of therapy in each patient. After analysis of these data, all patients were continued on the 300 mg lopinavir/75 mg ritonavir per m² dose. Patients had a mean age of 5 years (range 6 months to 12 years) with 14% less than 2 years. Mean baseline CD4+ cell count was 838

cells/mm³ and mean baseline plasma HIV-1 RNA was 4.7 log₁₀ copies/mL. Through 48 weeks of therapy, the proportion of patients who achieved and sustained an HIV-1 RNA < 400 copies/mL was 80% for antiretroviral naïve patients and 71% for antiretroviral experienced patients. The mean increase from baseline in CD4+ cell count was 404 cells/mm³ for antiretroviral naïve and 284 cells/mm³ for antiretroviral experienced patients. weeks. At 48 weeks, two patients (2%) had prematurely discontinued the study. One antiretroviral naïve patient prematurely discontinued secondary to an adverse reaction, while one antiretroviral experienced patient prematurely discontinued secondary to an HIV-1 related event.

Dose selection in pediatric patients was based on the following:

• Among patients 14 days to 6 months of age receiving 300/75 mg/m² twice daily without nevirapine, plasma concentrations were lower than those observed in adults or in older children. This dose resulted in HIV-1 RNA < 400 copies/mL in 55% of patients (70% in those initiating treatment at <6 weeks of age). Among patients 6 months to 12 years of age, the 230/57.5 mg/m² oral solution twice daily regimen without nevirapine and the 300/75 mg/m² oral solution twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen (without nevirapine). These doses resulted in treatment benefit (proportion of patients with HIV-1 RNA < 400 copies/mL) similar to that seen in the adult clinical trials. Among patients 12 to 18 years of age receiving 400/100 mg/m² or 480/120 mg/m² (with efavirenz) twice daily, plasma concentrations were 60 to 100% higher than among 6 to 12 year old patients receiving 230/57.5 mg/m². Mean apparent clearance was similar to that observed in adult patients receiving standard dose and in patients 6 to 12 years of age. Although changes in HIV-1 RNA in patients with prior treatment failure were less than anticipated, the pharmacokinetic data

supports use of similar dosing as in patients 6 to 12 years of age, not to exceed the recommended adult dose. For all age groups, the body surface area dosing was converted to body weight dosing using the patient's prescribed 16 HOW SUPPLIED/STORAGE AND HANDLING Lopinavir and Ritonavir Tablets, USP are available in the following strengths and package sizes:

Lopinavir and Ritonavir Tablets USP, 100 mg/25 mg: Yellow colored, film coated oval shaped biconvex tablets debossed with "LA59" on one side and plain on other side.

Bottles of 60 NDC 42385-933-60 Lopinavir and Ritonavir Tablets USP, 200 mg/50 mg: Yellow colored, film coated oval shaped biconvex tablets debossed with "LA58" on one side and plain on other side. Bottles of 120 NDC 42385-934-12 Recommended Storage:
Store lopinavir and ritonavir tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F)

[see USP controlled room temperature]. Dispense in original container or USP equivalent tight container For patient use: exposure of this product to high humidity outside the original container or USP equivalent tight container for longer than 2 weeks is not recor 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide) General Administration Information [see Dosage and Administration (2)]:

Advise patients to pay special attention to accurate administration of their dose to minimize the risk of accidental overdose

or underdose of lopinavir and ritonavir.

Advise patients and caregivers that the oral solution should be administered using the calibrated dosing cup (supplied) or oral dosing syringe.

Advise caregivers to inform their healthcare provider if the child's weight changes in order to make sure that the child's lopinavir and ritonavir dose is adjusted as needed. Inform patients and caregivers that lopinavir and ritonavir tablets may be taken with or without food but lopinavir and to the patients and caregivers that loginary and inclinary tablets may be taken with or without look but loginary and to tonavir oral solution should be taken with food to enhance absorption. Indivise patients to remain under the care of a healthcare provider while using lopinavir and ritonavir and to take lopinavir and ritonavir in combination with other antiretroviral drugs as prescribed. Advise patients not to alter the dose or discontinue therapy without consulting with their healthcare provider. If a dose of lopinavir and ritonavir is missed patients should take the dose as soon as possible and then return to their normal schedule.

However, if a dose is skipped the patient should not double the next dose. Inform patients that it is important to take lopinavir and ritonavir on a regular dosing schedule as directed and to avoid missing doses as that can result in development of resistance. Inform patients that there may be a greater chance of developing diarrhea with the once daily regimen as compared with the twice daily regimen.

Inform patients that lopinavir and ritonavir is not a cure for HIV-1 infection and that they may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections.

nform patients that lopinavir and ritonavir may interact with some drugs; therefore, patients should be advised to report to their healthcare provider the use of any prescription, non-prescription medication or herbal products such as St. John's Wort [see Contraindications (4), Warnings and Precautions (5.1) and Drug Interactions (7)].

Advise patients that pancreatitis has been observed in patients receiving lopinavir and ritonavir and to alert their healthcare provider if they experience symptoms such as nausea, vomiting or abdominal pain [see Warnings and Precautions (5.3)]. Inform patients that skin rash ranging in severity from mild to toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome

erythema multiforme, urticaria, and angioedema have been reported in patients receiving lopinavir and ritonavir or its components lopinavir and/or ritonavir. Advise patients to contact their healthcare provider if they develop a rash while taking lopinavir and ritonavir [see Adverse Reactions (6.1)]. Hepatotoxicity Pre-existing liver disease including Hepatitis B or C can worsen with use of lopinavir and ritonavir. This can be seen as worsening of transaminase elevations or hepatic decompensation. Advise patients that their liver function tests will need to be monitored

closely especially during the first several months of lopinavir and ritonavir treatment and that they should notify their healthcare provider if they develop the signs and symptoms of worsening liver disease including loss of appetite, abdominal pain, jaundice and itchy skin [see Warnings and Precautions (5.4)]. QT and PR Interval Prolongation Advise patients that lopinavir and ritonavir may produce changes in the electrocardiogram (e.g., PR and/or QT prolongation) and to consult their healthcare provider if they experience symptoms such as dizziness, lightheadedness, abnormal heart rhythm or loss of consciousness [see Warnings and Precautions (5.5, 5.6)].

Diabetes Mellitus/Hyperglycemia reported during lopinavir and ritonavir use. Advise patients to notify their healthcare provider if they develop the signs and rymptoms of diabetes mellitus including frequent urination, excessive thirst, extreme hunger or unusual weight loss and/or an increased blood sugar while on lopinavir and ritonavir as they may require a change in their diabetes treatment or new treatment [see Warnings and Precautions (5.7)].

Immune Reconstitution Syndrome antiretroviral therapy, including lopinavir and ritonavir [see Warnings and Precautions (5.8)] <u>Lipid Disorders</u>
Advise patients that treatment with lopinavir and ritonavir therapy can result in substantial increases in the concentration of total

cholesterol and triglycerides [see Warnings and Precautions (5.9)].

Fat Redistribution Advise patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long term health effects of these conditions are not known at this time [see Warnings and Precautions (5.10)]. Patients with Hemophilia Advise patients with hemophilia that they may experience increased bleeding when treated with protease inhibitors such as

opinavir and ritonavir [see Warnings and Precautions (5.11)]. Pregnancy Exposure Registry Inform patients that there is an antiretroviral pregnancy registry that monitors fetal outcomes of pregnant women exposed to lopinavir and ritonavir [see Use in Specific Populations (8.1)].

Instruct women with HIV-1 infection not to breastfeed because HIV-1 can be passed to the baby in breast milk [see Use in The brands listed are trademarks of their respective owners and are not trademarks of Laurus Labs Limited. The makers of these

brands are not affiliated with and do not endorse Laurus Labs Limited or its products Manufactured for: Laurus Generics Inc.

400 Connell Drive Suite 5200 Berkeley Heights, NJ 07922 Manufactured by: Laurus Labs Limited Anakapalli-531011

Nelfinavir+d4T+3TC

62%

25% 15%

4%

8%

MEDICATION GUIDE Lopinavir and Ritonavir (loe-PIN-a-veer and ri-TOE-na-vir) Tablets, USP

What is the most important information I should know about lopinavir and ritonavir?

Lopinavir and ritonavir may cause serious side effects, including: Interactions with other medicines, It is important to know the medicines that should not be taken with lopinavi and ritonavir. For more information, see "Who should not take lopinavir and ritonavir?"

Side Effects in babies taking lopinavir and ritonavir oral solution. Lopinavir and ritonavir oral solution contains alcohol (ethanol) and propylene glycol. Call your healthcare provider right away if your baby appears too sleepy or their Inflammation of your pancreas (pancreatitis). Lopinavir and ritonavir can cause pancreatitis which may be serious and may lead to death. People who have high levels of a certain fat (triglycerides) have a risk for developing pancreatitis. If you have advanced HIV-1 disease, you may have an increased risk of high triglyceride levels in your blood, and

pancreatitis. If you have a history of pancreatitis, you may have an increased risk of it coming back again during treatment with lopinavir and ritonavir. Tell your healthcare provider if you have any signs or symptoms of pancreatitis nausea

lurasidone

pimozide

ergot containing medicines including: dihydroergotamine mesylate

stomach-area (abdominal) pain Liver problems. Liver problems, including death, can happen in people who take lopinavir and ritonavir. Your healthcare provider should do blood tests before and during your treatment with lopinavir and ritonavir to check your liver function. If you have Hepatitis B or Hepatitis C, or other liver problems, you may have an increased risk for developing new or worsening of liver problems during treatment with lopinavir and ritonavir. Tell your healthcare provider right away if you have any signs and symptoms of liver problems including:

o pale colored stools loss of appetite itchy skin yellow skin and whites of eyes (jaundice) o stomach area (abdominal) pain dark-colored urine Changes in your heart rhythm and the electrical activity of your heart. These changes may be seen on an EKG (electrocardiogram) and can lead to serious heart problems. Your risk for these problems may be higher if you: have a history of abnormal heart rhythm or certain types of heart problems.

take other medicines that can affect your heart rhythm during treatment with lopinavir and ritonavir. Tell your healthcare provider right away if you have any of these symptoms dizziness fainting sensation of abnormal heartbeats lightheadedness

See "What are the possible side effects of lopinavir and ritonavir?" for more information about serious side effects. What is lopinavir and ritonavir?

Lopinavir and ritonavir is a prescription medicine that is used with other antiretroviral medicines to treat Human mmunodeficiency Virus-1 (HIV-1) infection in adults and children 14 days of age and older HIV is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).

It is not known if lopinavir and ritonavir is safe and effective in children under 14 days old. Who should not take lopinavir and ritonavir? Do not take lopinavir and ritonavir if you: are allergic to lopinavir, ritonavir, or any of the ingredients in lopinavir and ritonavir tablets. See the end of this Medication

Guide for a complete list of ingredients in lopinavir and ritonavir tablets if you take any of the following medicines: alfuzosin apalutamide dronedarone colchicine, if you have kidney or liver problems.

ergotamine tartrate methylergonovine cisapride elbasvir/grazoprevir simvastatin sildenafil (Revatio®), when used for the treatment of pulmonary arterial hypertension triazolam

nidazolam when taken by mouth St. John's Wort (Hypericum perforatum®) serious problems can happen if you or your child takes any of the medicines listed above with lopinavir and ritonavir. Before taking lopinavir and ritonavir, tell your healthcare provider about all of your medical conditions, including if you have or had pancreas problems.

have liver problems, including Hepatitis B or Hepatitis C. have any heart problems, including if you have a condition called Congenital Long QT Syndrome have low potassium in your blood. have high cholesterol in your blood.

have hemophilia. Lopinavir and ritonavir may cause increased bleeding. are pregnant or plan to become pregnant. It is not known if lopinavir and ritonavir will harm your unborn baby.

Lopinavir and ritonavir oral solution contains alcohol (ethanol) and propylene glycol. You should not take lopinavir and ritonavir oral solution during pregnancy because there is no safe level of alcohol exposure during pregnancy. Tell your healthcare provider if you become pregnant during treatment with lopinavir and ritonavir.

Lopinavir and ritonavir may reduce how well hormonal birth control works. Females who may become pregnant should use another effective form of birth control or an additional barrier method of birth control during treatmen

with lopinavir and ritonavir. Pregnancy Registry: There is a pregnancy registry for women who take antiretroviral medicines during pregnancy. The purpose of the pregnancy registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry.

are breastfeeding or plan to breastfeed. **Do not breastfeed if you take lopinavir and ritonavir.**You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby. Talk to your healthcare provider about the best way to feed your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines vitamins, and herbal supplements. Many medicines interact with lopinavir and ritonavir. Keep a list of your medicines to show your healthcare provider and pharmacist. You can ask your healthcare provider or pharmacist for a list of medicines that interact with lopinavir and ritonavir. Do not start taking a new medicine without telling your healthcare provider. Your healthcare provider can tell you if it is safe to take lopinavir and ritonavir with other medicines. Your healthcare provider may need to change the dose of other edicines during treatment with lopinavir and ritonavir.

How should I take lopinavir and ritonavir? Take lopinavir and ritonavir every day exactly as prescribed by your healthcare provide Stay under the care of your healthcare provider during treatment with lopinavir and ritonavir. It is important to set up a dosing schedule and follow it every day. Do not change your treatment or stop treatment without first talking with your healthcare provider Swallow lopinavir and ritonavir tablets whole. Do not chew, break, or crush lopinavir and ritonavir tablets. Lopinavir and ritonavir tablets can be taken with or without food.

Lopinavir and ritonavir oral solution must be taken with food. If you are taking both didanosine and lopinavir and ritonavir:

Didanosine can be taken at the same time as lopinavir and ritonavir tablets, without food. Take didanosine either 1 hour before or 2 hours after taking lopinavir and ritonavir oral solution.

If you are pregnant:

You should not take lopinavir and ritonavir tablets on a 1 time each day dose schedule. Avoid use of lopinavir and ritonavir oral solution

If your child is prescribed lopinavir and ritonavir:

Tell your healthcare provider if your child's weight changes.

Lopinavir and ritonavir should not be given to children on a 1 time each day dose schedule. When giving lopinavir and ritonavir to your child, give lopinavir and ritonavir exactly as prescribed.

Use the dosing cup (supplied) or an oral syringe with mL (milliliter) markings to give the prescribed dose of lopinav and ritonavir oral solution to your child. Your pharmacist should provide an oral syringe to you. Lopinavir and ritonavir oral solution contains propylene glycol and a large amount of alcohol (ethanol). Lopinavir and ritonavir oral solution should not be given to babies younger than 14 days of age unless your healthcare

provider thinks it is right for your baby. You may have a greater chance of getting diarrhea if you take lopinavir and ritonavir 1 time each day than if you take it 2 times each day. Do not miss a dose of lopinavir and ritonavir. This could make the virus harder to treat. If you forget to take lopinavir and ritonavir, take the missed dose right away. If it is almost time for your next dose, **do not** take the missed dose. Instead, follow your regular dosing schedule by taking your next dose at its regular time. **Do not** take more than one dose of lopinavir and ritonavir at one time.

If you or your child take more than the prescribed dose of lopinavir and ritonavir, call your healthcare provide or go to the nearest emergency room right away. What are the possible side effects of lopinavir and ritonavir? Lopinavir and ritonavir can cause serious side effects, including See "What is the most important information I should know about lopinavir and ritonavir?" Diabetes and high blood sugar (hyperglycemia). You may develop new or worsening diabetes or high blood sugar during treatment with lopinavir and ritonavir. Tell your healthcare provider if you get any of the following signs or

urinate more often than usual unusual weight loss increased hunger or thirst increase in your blood sugar levels ur healthcare provider may need to start you on medicine to treat high blood sugar or change your diabetes medicines.

Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a

long time. Call your healthcare provider right away if you start having new symptoms after starting your HIV-1 medicine.

Increases in certain fat (triglycerides and cholesterol) levels in your blood. Large increases of triglycerides and cholesterol can be seen in blood test results of some people who take lopinavir and ritonavir. Your healthcare provider should do blood tests to check your cholesterol and triglyceride levels before you start taking lopinavir and ritonavir and during your treatment Changes in body fat can happen in some people who take antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck ("buffalo hump"), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms and face may also happen. The exact cause and long-term health effects of these conditions

Increased bleeding in people with hemophilia. Some people with hemophilia have increased bleeding with lopinal Skin rash, which can be severe, can happen in people who take lopinavir and ritonavir. Tell your healthcare provider if you have a history of skin rash with other medicine used to treat your HIV-1 infection or if you get any skin rash during treatment with lopinavir and ritonavir. Kidney stones

 vomiting • increased fats in blood (triglycerides or cholesterol) hese are not all of the possible side effects of lopinavir and ritonavir. For more information, ask your healthcare provider c Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. low should I store Lopinavir and Ritonavir?

nmon side effects of lopinavir and ritonavir include:

Lopinavir and ritonavir tablets: Store lopinavir and ritonavir tablets at room temperature, between 68°F to 77°F (20°C to 25°C). Store lopinavir and ritonavir tablets in the original container.

Do not keep lopinavir and ritonavir tablets in the original container.

Do not keep lopinavir and ritonavir tablets out of the container it comes in for longer than 2 weeks, especially in areas where there is a lot of humidity

Keep lopinavir and ritonavir and all medicines out of the reach of children General information about the safe and effective use of lopinavir and ritonavir Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lopinavir and ritonavir for a condition for which it was not prescribed. Do not give lopinavir and ritonavir to other people, even if they have the same condition you have. It may harm them

You can ask your pharmacist or healthcare provider for information about lopinavir and ritonavir that is written for health What are the ingredients in lopinavir and ritonavir tablets? Active ingredients: lopinavir and ritonavir

Lopinavir and Ritonavir Tablets USP, 200 mg/50 mg: colloidal silicon dioxide, copovidone, sodium stearyl fumarate and sorbitan monolaurate. The following are the ingredients in the film coating: colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, iron oxide yellow, polyethylene glycol 400, polyethylene glycol 3350, polysorbate 80, talc, and titanium dioxide. Lopinavir and Ritonavir Tablets USP, 100 mg/25 mg: colloidal silicon dioxide, copovidone, sodium stearyl fumarate and sorbitan monolaurate. The following are the ingredients in the film coating; colloidal silicon dioxide, hydroxypropyl cellulose romellose, iron oxide yellow, polyethylene glycol 400, polyethylene glycol 3350, polysorbate 80, talc, and titanium dioxide

For more information, call Laurus Generics Inc. at 1-833-3-LAURUS (1-833-352-8787). The brands listed are trademarks of their respective owners and are not trademarks of Laurus Labs Limited. The makers of these brands are not affiliated with and do not endorse Laurus Labs Limited or its products This Medication Guide has been approved by the U.S. Food and Drug Administration Manufactured for: Laurus Generics Inc.

400 Connell Drive, Suite 5200 Berkeley Heights, NJ 07922 Manufactured by:

makapalli-531011 Revised: 05/2023

lanufactured for:
aurus Generics Inc.
aurus Generics Inc.
00 Connell Drive, Suit
erkeley Heights, NJ 0
lanufactured by:
aurus Labs Limited
nakapalli-531011

Active ingredients: lopinavir Inactive ingredients:
Lopinavir and Ritonavir Ta

copovidone, sodium stearyl furmarate and sorbit the ingredients in the film coating: colloidal silicol hypromellose, iron oxide yellow, polyethylene gly polysorbate 80, talc, and titanium dioxide.

Lopinavir and Ritonavir Tablets USP, 100 mg copovidone, sodium stearyl furmarate and sorbite the ingredients in the film coating: colloidal silicor hypromellose, iron oxide yellow, polyethylene glypolysorbate 80, talc, and titanium dioxide.

For more information, call Laurus Generics Inc. at 1. glycol mg/50 rbitan m n monolaurate. The following are dioxide, hydroxypropyl cellulose, ol 400, polyethylene glycol 3350,

Medicines are sometimes prescribed for purposes of Medication Guide. Do not use lopinavir and ritonavir for Medication Guide. Do not give lopinavir and ritonavir to oth the same condition you have. It may harm them. You can ask your pharmacist or healthcare provider for and ritonavir that is written for health professionals.

What are the ingredients in lopinavir and ritonavir to the same conditions are the ingredients in lopinavir and ritonavir to the same conditions. ό r people,

lopinavir

information about the

safe

and effective use

of lopinavir

listed vhich it listed in a hich it was f they have

f children. and

⊒.

ο̈́

ō

77

 diarrhea
 nausea
 increased fats in blood (triglyceride nausea)
 increased fats in blood (triglyceride nausea)
 These are not all of the possible side effects of lopinavir and information, ask your healthcare provider or pharmacist.
 Call your doctor for medical advice about side effects. You may FDA at 1-800-FDA-1088.
 How should I store Lopinavir and Ritonavir?
 Lopinavir and ritonavir tablets:
 Store lopinavir and ritonavir tablets at room temperature, be (20°C to 25°C).
 Store lopinavir and ritonavir tablets in the original container.
 Do not keep lopinavir and ritonavir tablets out of the container than 2 weeks, especially in areas where there is a lot longer than 2 weeks. Store lopinavir and ritonavir tablets in Do not keep lopinavir and ritonavir ta longer than 2 weeks, especially in arkeep the container closed tightly.

Keep lopinavir and ritonavir and all m ontainer it comes in a lot of humidity. between

yycerides of lopinavir and macist may report side

effects t

ţ

9 lopinavir and For

Your healthcare provider may need to start you on medicine to treat high blood sugar or change your diabetes medicines.

• Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Call your healthcare provider right away if you start having new symptoms after starting your HIV-1 medicine.

• Increases in certain fat (triglycerides and cholesterol) levels in your blood. Large increases of triglycerides and cholesterol can be seen in blood test results of some people who take lopinavir and ritonavir. Your healthcare provider should do blood tests to check your cholesterol and triglyceride levels before you start taking lopinavir and ritonavir and during your treatment.

• Changes in body fat can happen in some people who take antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck ("buffalo hump"), breast, and around the middle of your body (trunk). Loss of fat from the legs, arms and face may also happen. The exact cause and long-term health effects of these conditions are not known at this time.

• Increased bleeding in people with hemophilia. Some people with hemophilia have increased bleeding with lopinavir and ritonavir or similar medicines.

• Skin rash, which can be severe, can happen in people who take lopinavir and ritonavir. Tell your healthcare provider if you have a history of skin rash with other medicine used to treat your HIV-1 infection or if you get any skin rash during treatment with lopinavir and ritonavir.

unusual weight loss increase in your blood levels

• See "What is the most important information I should kn and ritonavir?"
• Diabetes and high blood sugar (hyperglycemia). You m worsening diabetes or high blood sugar during treatment ritonavir. Tell your healthcare provider if you get any of the symptoms: h blood sugar (hyperglycemia). You sor high blood sugar during treatment healthcare provider if you get any of ou may develop new onent with lopinavir an of the following signs of 요절요

Schedules

Avoid use of lopinavir and ritonavir:

Avoid use of lopinavir and ritonavir:

Tell your child is prescribed lopinavir and ritonavir:

Tell your healthcare provider if your child's weight changes.

Lopinavir and ritonavir should not be given to children on a 1 time each day dose schedule. When giving lopinavir and ritonavir to your child, give lopinavir and ritonavir exactly as prescribed.

Use the dosing cup (supplied) or an oral syringe with mL (milliliter) markings to give the prescribed dose of lopinavir and ritonavir oral solution to your child. Your pharmacist should provide an oral syringe to you.

Lopinavir and ritonavir oral solution contains propylene glycol and a large amount of alcohol (ethanol). Lopinavir and ritonavir oral solution should not be given to babies younger than 14 days of age unless your healthcare provider thinks it is right for your baby.

You may have a greater chance of getting diarrhea if you take lopinavir and ritonavir. This could make the virus harder to treat. If you forget to take lopinavir and ritonavir, take the missed dose inght away. If it is almost time for your next dose, do not take the missed dose instead, follow your regular dosing schedule by taking your next dose at its regular time. Do not take more than one dose of lopinavir and ritonavir, at one time.

If you or your child take more than the prescribed dose of lopinavir and ritonavir at one time.

If you or your child take more than the prescribed dose of lopinavir and ritonavir and ritonavir?

Lopinavir and ritonavir can cause serious side effects, including:

See "What is the most important information I should know about lopinavir and ritonavir and high blood sugar (hyperglycemia). You may develop new or hans of dose of during the time.

It is important to set up a dosing schedule and follow it every day.

Do not change your treatment or stop treatment without first talking healthcare provider.

Swallow lopinavir and ritonavir tablets whole. Do not chew, break, lopinavir and ritonavir tablets.

Lopinavir and ritonavir tablets can be taken with or without food.

Lopinavir and ritonavir oral solution must be taken with food.

If you are taking both didanosine and lopinavir and ritonavir:

Didanosine can be taken at the same time as lopinavir and ritonavir. Take didanosine either ritonavir oral solution. pregnant: **ould not** take lopinavir and ritonavir tablets on 익 after taking and ritonavir

If you a

0

with Q your

Back Page